data_1g26_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1g26 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.52 ' CG2' HD11 ' A' ' 9' ' ' ILE . 10.8 m . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.248 0.547 . . . . 0.0 110.275 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' A' ' 4' ' ' CYS . 23.4 t -99.08 82.6 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 110.086 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.511 ' ND1' ' N ' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -51.59 89.77 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 110.476 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.492 ' N ' ' O ' ' A' ' 2' ' ' VAL . 88.8 m -60.14 -19.46 53.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.91 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.461 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 1.8 t0 177.9 -170.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.517 -0.739 . . . . 0.0 109.841 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 12.5 mtt -91.75 14.08 16.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.078 -1.014 . . . . 0.0 110.436 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -127.78 3.02 6.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.886 . . . . 0.0 110.056 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.5 p -168.48 154.44 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.37 -0.831 . . . . 0.0 110.098 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.52 HD11 ' CG2' ' A' ' 1' ' ' VAL . 8.8 tt -146.39 125.52 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.921 . . . . 0.0 110.032 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.457 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 67.3 m -127.95 137.16 30.2 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.18 -0.95 . . . . 0.0 110.219 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.601 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 43.1 Cg_endo -73.06 152.88 51.73 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.838 1.441 . . . . 0.0 110.595 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.457 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 0.6 OUTLIER -37.24 -44.47 0.58 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.719 -0.613 . . . . 0.0 111.487 -179.606 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -62.58 -3.42 5.54 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.7 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . 0.601 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 17.9 m-85 -124.26 154.26 40.48 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.445 -1.621 . . . . 0.0 111.52 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.5 p -107.34 137.65 44.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.534 -0.728 . . . . 0.0 109.778 179.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.76 142.38 27.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 110.33 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.96 149.21 48.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.302 -0.873 . . . . 0.0 109.983 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.563 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -103.63 129.41 50.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.155 -0.966 . . . . 0.0 110.188 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.543 ' HB2' ' CB ' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -69.78 168.61 16.51 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 110.128 -179.94 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -74.7 2.17 6.75 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 124.009 1.531 . . . . 0.0 110.695 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -122.53 33.27 5.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.088 -1.008 . . . . 0.0 110.417 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.53 30.24 73.06 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.543 ' CB ' ' HB2' ' A' ' 19' ' ' LEU . . . -108.27 -174.14 2.45 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.248 -1.148 . . . . 0.0 110.272 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.563 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 31.7 m95 -137.84 147.88 44.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.883 . . . . 0.0 110.276 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.72 156.34 26.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.8 t -118.75 135.57 54.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -1.158 . . . . 0.0 110.527 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.61 125.49 11.99 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.32 164.81 34.23 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 123.787 1.414 . . . . 0.0 110.354 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.91 . . . . 0.0 110.222 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.465 HG13 HG22 ' A' ' 9' ' ' ILE . 1.4 t . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.148 0.499 . . . . 0.0 109.692 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.48 ' CG2' ' O ' ' A' ' 2' ' ' VAL . 24.9 m -112.43 80.25 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.07 -1.019 . . . . 0.0 110.108 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.409 ' C ' ' O ' ' A' ' 2' ' ' VAL . 1.4 m-70 -42.83 125.63 3.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.298 -0.876 . . . . 0.0 110.3 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -101.67 -40.0 7.19 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 110.053 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -145.46 -166.91 2.55 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.862 . . . . 0.0 110.017 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -61.21 -50.19 74.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.155 -0.966 . . . . 0.0 110.244 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.459 ' O ' ' CG ' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -126.17 61.22 1.28 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 110.293 -179.824 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -167.19 119.62 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.269 -0.894 . . . . 0.0 109.696 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.48 HG22 ' N ' ' A' ' 10' ' ' CYS . 3.4 mt -131.62 162.32 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.182 -0.949 . . . . 0.0 110.666 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.508 ' SG ' ' CB ' ' A' ' 14' ' ' TYR . 0.1 OUTLIER -136.28 136.31 22.31 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.275 -0.89 . . . . 0.0 109.57 179.523 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.641 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 42.5 Cg_endo -71.27 53.79 1.7 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.753 1.396 . . . . 0.0 111.656 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.509 ' O ' ' N ' ' A' ' 14' ' ' TYR . 19.0 t0 54.12 -77.57 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.59 -0.694 . . . . 0.0 111.808 178.598 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -37.16 -28.93 0.03 OUTLIER Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . 0.641 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 24.9 m-85 -92.0 161.88 14.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.118 -1.225 . . . . 0.0 110.657 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -119.78 145.2 46.8 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.369 -0.832 . . . . 0.0 110.04 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.22 140.52 36.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -0.851 . . . . 0.0 110.358 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.62 117.14 6.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.256 -0.903 . . . . 0.0 110.119 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.416 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -72.06 149.34 44.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.121 -0.987 . . . . 0.0 109.979 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.422 ' HB2' ' HB1' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -89.36 170.4 10.84 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.188 -0.945 . . . . 0.0 110.566 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.07 -3.66 14.05 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 124.054 1.555 . . . . 0.0 110.277 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.5 m -109.33 25.64 11.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.299 -0.876 . . . . 0.0 110.038 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.39 51.54 42.28 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.422 ' HB1' ' HB2' ' A' ' 19' ' ' LEU . . . -136.95 -173.2 3.38 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.179 -1.189 . . . . 0.0 110.237 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -120.85 148.31 44.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.226 -0.921 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.74 125.52 1.82 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -96.99 130.24 44.34 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.286 -1.126 . . . . 0.0 109.716 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 95.6 m -126.88 153.11 76.14 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.149 -0.97 . . . . 0.0 110.568 -179.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.93 151.85 51.14 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.12 1.589 . . . . 0.0 110.266 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 110.44 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.406 HG13 HG23 ' A' ' 2' ' ' VAL . 73.1 t . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.254 0.549 . . . . 0.0 110.2 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.406 HG23 HG13 ' A' ' 1' ' ' VAL . 22.0 t -97.66 72.34 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.145 -0.972 . . . . 0.0 109.86 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.511 ' CE1' HG21 ' A' ' 9' ' ' ILE . 24.8 m-70 -46.05 106.67 0.08 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.339 -0.851 . . . . 0.0 110.668 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.475 ' HB3' ' O ' ' A' ' 8' ' ' VAL . 7.1 t -89.01 -25.64 21.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.259 -0.901 . . . . 0.0 109.632 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -156.87 -139.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.386 -0.821 . . . . 0.0 109.764 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 55.1 mtm -79.82 -50.5 10.44 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.1 -1.0 . . . . 0.0 110.023 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -122.89 -1.31 8.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.29 -0.881 . . . . 0.0 110.22 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.475 ' O ' ' HB3' ' A' ' 4' ' ' CYS . 45.0 t -89.97 75.77 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.187 -0.946 . . . . 0.0 110.252 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.511 HG21 ' CE1' ' A' ' 3' ' ' HIS . 6.8 pt -112.07 126.82 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.058 -1.026 . . . . 0.0 109.997 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -109.95 157.92 36.44 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.28 -0.887 . . . . 0.0 110.172 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.471 ' HD2' ' CD1' ' A' ' 14' ' ' TYR . 48.2 Cg_endo -81.15 41.06 1.08 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.873 1.46 . . . . 0.0 110.944 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.426 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 0.3 OUTLIER 66.34 -57.97 0.36 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.051 -1.031 . . . . 0.0 110.817 179.528 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.0 -25.02 0.59 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . 0.471 ' CD1' ' HD2' ' A' ' 11' ' ' PRO . 54.3 m-85 -96.04 163.66 13.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.035 -1.274 . . . . 0.0 110.826 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.519 ' CG2' ' O ' ' A' ' 27' ' ' CYS . 0.7 OUTLIER -113.62 131.14 56.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.473 -0.767 . . . . 0.0 109.459 179.018 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.4 t -90.54 102.38 15.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.518 -0.739 . . . . 0.0 110.373 -179.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -112.25 137.57 50.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.836 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.2 mtm105 -92.11 131.86 37.05 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 110.055 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.475 ' CG ' ' HD2' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -67.67 165.76 27.96 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.335 -0.853 . . . . 0.0 110.138 179.977 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.475 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 43.9 Cg_endo -69.62 -5.29 15.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.962 1.507 . . . . 0.0 110.325 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.15 26.99 7.03 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.413 -0.804 . . . . 0.0 110.113 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.83 27.23 72.55 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -109.38 171.0 7.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.13 -1.218 . . . . 0.0 110.389 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.1 m95 -111.2 150.51 29.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.304 -0.872 . . . . 0.0 109.864 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.76 109.27 0.41 Allowed Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.086 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -93.52 115.94 28.46 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.214 -1.168 . . . . 0.0 109.65 179.222 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.519 ' O ' ' CG2' ' A' ' 15' ' ' THR . 25.0 p -129.93 153.2 80.93 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.135 -0.978 . . . . 0.0 110.586 -179.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.82 149.84 48.64 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.045 1.55 . . . . 0.0 110.244 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 29' ' ' PHE . 72.4 t80 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.23 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 28.4 m . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.236 0.541 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.499 ' HB ' ' O ' ' A' ' 10' ' ' CYS . 21.0 t -108.04 100.82 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.916 . . . . 0.0 110.117 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -81.53 89.84 6.21 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.197 -0.939 . . . . 0.0 110.105 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 44.9 m -84.74 4.45 32.69 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.21 -0.931 . . . . 0.0 110.381 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -168.88 -166.45 0.65 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.19 -0.944 . . . . 0.0 110.359 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 24.2 mtm -97.07 -27.15 14.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 110.603 -179.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -108.41 -47.83 3.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.098 -1.001 . . . . 0.0 110.769 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.484 ' C ' ' CG2' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -90.09 137.93 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.097 -1.002 . . . . 0.0 110.27 -179.821 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.484 ' CG2' ' C ' ' A' ' 8' ' ' VAL . 4.4 pt -151.2 131.19 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.258 -0.901 . . . . 0.0 110.092 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.499 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 20.5 m -122.71 162.68 37.25 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.957 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -82.93 173.34 10.27 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.736 1.388 . . . . 0.0 110.564 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -63.79 -19.22 64.83 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.288 -0.883 . . . . 0.0 111.217 -179.107 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.14 -4.91 38.39 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -132.24 175.16 9.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.032 -1.275 . . . . 0.0 110.956 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.0 p -128.56 119.01 24.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.626 -0.671 . . . . 0.0 109.331 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.419 ' O ' ' SG ' ' A' ' 16' ' ' CYS . 28.9 p -82.15 123.47 29.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.241 -0.912 . . . . 0.0 110.654 -179.287 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 m -118.05 127.4 53.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.487 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -82.37 122.68 28.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.186 -0.946 . . . . 0.0 110.331 -179.787 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.541 ' HB2' ' CB ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -67.66 170.37 7.2 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.175 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.499 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 47.9 Cg_endo -72.98 -20.02 22.5 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 O-C-N 124.049 1.552 . . . . 0.0 110.661 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.8 m -99.14 31.66 2.97 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.17 -0.956 . . . . 0.0 110.074 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.62 41.54 93.93 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.541 ' CB ' ' HB2' ' A' ' 19' ' ' LEU . . . -114.94 -172.74 2.18 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.174 -1.192 . . . . 0.0 110.336 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.487 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 20.3 m95 -140.04 147.95 41.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.927 . . . . 0.0 110.236 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 113.84 0.81 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.67 106.47 18.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -1.162 . . . . 0.0 109.993 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.8 m -119.21 139.39 27.46 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 110.232 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.47 148.22 47.86 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.017 1.535 . . . . 0.0 110.646 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 4.7 t80 . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.404 -0.81 . . . . 0.0 109.872 179.854 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.5 m . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.288 0.566 . . . . 0.0 110.309 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 4' ' ' CYS . 3.1 p -122.32 88.88 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.34 -0.85 . . . . 0.0 110.059 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.508 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -59.07 82.32 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 110.429 -179.71 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.479 ' N ' ' O ' ' A' ' 2' ' ' VAL . 0.4 OUTLIER -54.13 -28.46 39.88 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.189 -0.944 . . . . 0.0 109.817 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.91 -163.79 1.86 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.356 -0.84 . . . . 0.0 109.892 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -98.96 15.57 25.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.077 -1.014 . . . . 0.0 110.601 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.479 ' HG3' ' N ' ' A' ' 8' ' ' VAL . 11.1 pt-20 -136.61 -33.16 0.8 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.102 -0.999 . . . . 0.0 110.651 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.479 ' N ' ' HG3' ' A' ' 7' ' ' GLU . 9.4 p -116.49 162.44 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.085 -1.009 . . . . 0.0 110.401 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.45 ' N ' HG23 ' A' ' 8' ' ' VAL . 3.5 tt -157.55 133.97 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.292 -0.88 . . . . 0.0 110.323 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.414 ' O ' ' CG1' ' A' ' 2' ' ' VAL . 51.2 m -107.73 144.18 28.78 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.082 -1.011 . . . . 0.0 109.589 179.489 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 13' ' ' GLY . 46.7 Cg_endo -80.33 38.01 0.72 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.675 1.355 . . . . 0.0 111.267 -179.738 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 3.0 t0 66.32 -56.33 0.38 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 110.859 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.22 -31.78 0.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . 0.515 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 47.5 m-85 -103.36 173.14 6.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.196 -1.179 . . . . 0.0 110.309 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.519 ' CG2' ' CD1' ' A' ' 29' ' ' PHE . 37.5 p -115.54 125.88 53.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.423 -0.798 . . . . 0.0 109.969 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 8.1 t -49.09 126.37 12.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 110.22 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.3 m -146.55 142.07 27.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 110.153 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.588 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -97.03 141.98 29.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 110.401 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -76.3 160.32 78.07 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 0.0 110.181 179.904 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.52 -6.97 20.06 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.985 1.518 . . . . 0.0 110.653 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.445 ' O ' ' OG ' ' A' ' 21' ' ' SER . 3.2 t -107.41 29.58 7.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 110.307 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.05 67.45 1.96 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.449 ' HB2' ' HB2' ' A' ' 19' ' ' LEU . . . -155.13 174.43 15.2 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -1.107 . . . . 0.0 110.148 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.588 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 14.6 m95 -123.06 147.63 46.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.237 -0.914 . . . . 0.0 110.252 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -165.94 155.24 26.38 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.45 ' HB3' ' HB2' ' A' ' 14' ' ' TYR . 7.8 m -98.33 125.75 43.58 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.223 -1.163 . . . . 0.0 109.862 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 1.1 m -109.61 129.45 23.91 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.156 -0.965 . . . . 0.0 110.397 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.78 155.15 54.03 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.782 1.411 . . . . 0.0 109.9 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' A' ' 29' ' ' PHE . 4.6 p90 . . . . . 0 N--CA 1.49 1.573 0 O-C-N 121.124 -0.985 . . . . 0.0 110.859 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.533 ' HB ' ' CD1' ' A' ' 9' ' ' ILE . 6.9 m . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.31 0.576 . . . . 0.0 110.22 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.53 HG21 ' CB ' ' A' ' 12' ' ' ASP . 44.6 t -105.5 103.72 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 110.292 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.405 ' C ' ' O ' ' A' ' 2' ' ' VAL . 14.2 m-70 -44.02 118.75 1.55 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.186 -0.946 . . . . 0.0 110.493 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -79.93 -37.77 33.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.322 -0.861 . . . . 0.0 109.693 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -169.54 -80.08 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.451 -0.781 . . . . 0.0 110.276 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 9.4 tpp -146.15 -53.79 0.26 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.136 -0.977 . . . . 0.0 110.59 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -102.84 13.14 35.11 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.104 -0.997 . . . . 0.0 110.205 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -138.17 141.08 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.345 -0.847 . . . . 0.0 110.08 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.533 ' CD1' ' HB ' ' A' ' 1' ' ' VAL . 0.0 OUTLIER -145.15 127.96 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 110.004 -179.825 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 14' ' ' TYR . 0.5 OUTLIER -118.65 154.85 52.74 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.053 -1.03 . . . . 0.0 110.297 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.478 ' O ' ' N ' ' A' ' 13' ' ' GLY . 48.0 Cg_endo -78.59 43.14 1.38 Allowed 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.964 1.508 . . . . 0.0 111.434 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.53 ' CB ' HG21 ' A' ' 2' ' ' VAL . 3.8 t70 65.05 -58.95 0.26 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 111.137 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.41 -26.48 0.22 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . 0.489 ' CE2' ' HB3' ' A' ' 28' ' ' PRO . 92.1 m-85 -100.87 153.43 19.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.952 -1.322 . . . . 0.0 110.955 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.521 ' CG2' ' O ' ' A' ' 27' ' ' CYS . 10.1 t -102.43 146.18 28.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 109.784 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -94.74 122.11 37.01 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.34 -0.85 . . . . 0.0 110.684 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -139.77 144.1 37.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.38 -0.825 . . . . 0.0 109.571 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.576 ' HG3' ' CH2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -92.34 134.76 34.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.511 -179.581 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.479 ' CG ' ' HD2' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -64.59 171.93 2.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.386 -0.821 . . . . 0.0 110.431 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.479 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 49.9 Cg_endo -76.2 1.55 8.17 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.062 1.559 . . . . 0.0 110.713 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 69.0 m -117.69 29.56 7.77 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.211 -0.93 . . . . 0.0 110.483 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.49 58.58 9.09 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.475 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . -145.56 168.29 20.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.299 -1.118 . . . . 0.0 109.857 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.576 ' CH2' ' HG3' ' A' ' 18' ' ' ARG . 2.0 m95 -105.14 147.6 27.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.126 -0.984 . . . . 0.0 110.203 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -154.02 133.63 4.0 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.19 128.31 48.75 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -1.157 . . . . 0.0 110.008 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.521 ' O ' ' CG2' ' A' ' 15' ' ' THR . 76.7 m -124.38 133.15 24.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 110.379 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.489 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 50.1 Cg_endo -75.48 149.8 35.28 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.867 1.456 . . . . 0.0 110.249 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.57 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 11.7 p90 . . . . . 0 N--CA 1.493 1.702 0 O-C-N 121.213 -0.93 . . . . 0.0 110.321 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 121.348 0.594 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 89.3 t -105.96 -25.34 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.94 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 56.07 93.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.333 -0.854 . . . . 0.0 110.348 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.3 m -61.93 -36.95 82.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.915 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -163.4 -153.61 0.25 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.298 -0.876 . . . . 0.0 110.332 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -80.82 -15.74 55.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.227 -0.92 . . . . 0.0 110.619 -179.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.421 ' C ' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -135.35 23.23 3.46 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.222 -0.924 . . . . 0.0 110.514 -179.813 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.421 HG22 ' C ' ' A' ' 7' ' ' GLU . 16.6 t -142.98 149.29 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.09 -1.006 . . . . 0.0 110.254 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 6.2 tt -163.04 143.22 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.228 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.421 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -119.94 168.98 9.18 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.864 . . . . 0.0 110.145 -179.918 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.47 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.3 Cg_endo -80.25 38.84 0.78 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 124.092 1.575 . . . . 0.0 111.198 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.47 ' HB2' ' O ' ' A' ' 11' ' ' PRO . 1.4 m-20 66.69 138.19 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 120.948 -1.095 . . . . 0.0 110.377 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.48 42.88 7.64 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . 0.47 ' CD1' ' HA ' ' A' ' 28' ' ' PRO . 22.0 m-85 -150.59 151.91 33.29 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.201 -1.176 . . . . 0.0 110.543 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.442 ' CG2' ' HB2' ' A' ' 27' ' ' CYS . 5.7 t -104.98 146.68 28.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.803 . . . . 0.0 110.109 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.7 m -97.83 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.305 -0.872 . . . . 0.0 110.226 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.8 m -111.0 127.15 55.43 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.194 -0.941 . . . . 0.0 110.152 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.556 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -85.69 124.79 32.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.121 -0.987 . . . . 0.0 110.435 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.453 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -72.0 161.73 77.24 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.29 -0.881 . . . . 0.0 110.054 179.924 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -74.16 -5.83 17.56 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.951 1.501 . . . . 0.0 110.548 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 t -111.56 31.81 5.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.27 -0.894 . . . . 0.0 110.246 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.67 68.75 1.55 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.453 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -155.58 179.6 9.03 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.317 -1.108 . . . . 0.0 110.182 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.556 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 24.8 m95 -134.57 147.27 50.23 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -0.865 . . . . 0.0 110.18 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.8 133.31 6.31 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -97.25 112.56 24.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -1.166 . . . . 0.0 110.29 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.442 ' HB2' ' CG2' ' A' ' 15' ' ' THR . 1.3 m -105.56 144.43 28.83 Favored Pre-proline 0 N--CA 1.493 1.675 0 O-C-N 121.309 -0.869 . . . . 0.0 110.067 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HA ' ' CD1' ' A' ' 14' ' ' TYR . 44.0 Cg_endo -70.92 149.08 58.92 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.805 1.424 . . . . 0.0 110.717 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 1.8 t80 . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 110.328 -179.93 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 20.0 m . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.202 0.525 . . . . 0.0 110.271 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 3' ' ' HIS . 85.4 t -107.69 146.78 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.298 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.451 ' N ' HG13 ' A' ' 2' ' ' VAL . 10.9 t60 -70.56 80.78 0.58 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.2 -0.938 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.479 ' HB3' ' HB ' ' A' ' 8' ' ' VAL . 3.7 t -40.8 -52.98 2.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.395 -0.816 . . . . 0.0 110.536 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 1.2 t0 -145.46 -147.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.125 -0.985 . . . . 0.0 110.288 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -78.04 -33.81 50.82 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.227 -0.92 . . . . 0.0 110.444 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -126.93 20.47 7.0 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.107 -0.996 . . . . 0.0 110.471 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.479 ' HB ' ' HB3' ' A' ' 4' ' ' CYS . 16.3 t -126.8 152.52 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.282 -0.886 . . . . 0.0 109.931 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.458 ' CG2' ' O ' ' A' ' 9' ' ' ILE . 0.7 OUTLIER -146.04 105.82 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.095 -1.003 . . . . 0.0 110.825 -179.619 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.45 ' O ' ' N ' ' A' ' 2' ' ' VAL . 84.1 m -121.07 161.19 41.82 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.267 -0.895 . . . . 0.0 109.546 179.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.585 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 40.5 Cg_endo -72.71 154.99 54.49 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.787 1.414 . . . . 0.0 110.881 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -48.86 -19.16 0.35 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.564 -0.71 . . . . 0.0 111.544 -178.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.431 ' O ' ' CD1' ' A' ' 14' ' ' TYR . . . -87.24 32.27 4.17 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . 0.585 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 11.6 m-85 -140.78 162.35 35.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.064 -1.257 . . . . 0.0 110.833 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.514 ' CG2' ' O ' ' A' ' 27' ' ' CYS . 1.0 OUTLIER -128.99 118.27 22.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.519 -0.738 . . . . 0.0 109.419 179.482 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 130.44 40.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.375 -0.828 . . . . 0.0 110.863 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -144.02 131.17 20.65 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.704 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.4 132.26 35.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 110.21 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.468 ' HB2' ' CB ' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -62.98 165.35 10.37 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.337 -0.852 . . . . 0.0 110.093 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -80.01 41.58 1.15 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.955 1.503 . . . . 0.0 110.848 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -168.33 30.05 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.029 -1.044 . . . . 0.0 110.488 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.78 61.47 3.09 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.468 ' CB ' ' HB2' ' A' ' 19' ' ' LEU . . . -151.41 170.68 18.98 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.314 -1.109 . . . . 0.0 110.097 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.433 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 1.7 m95 -116.19 149.22 39.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.139 -0.975 . . . . 0.0 110.466 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.76 123.57 1.03 Allowed Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 15' ' ' THR . 26.3 p -97.28 130.09 44.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 110.235 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.514 ' O ' ' CG2' ' A' ' 15' ' ' THR . 0.0 OUTLIER -100.0 150.07 36.55 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.26 -0.9 . . . . 0.0 109.906 179.851 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.97 145.89 63.25 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.797 1.42 . . . . 0.0 110.58 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.528 -0.733 . . . . 0.0 109.982 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.1 m . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.16 0.505 . . . . 0.0 110.236 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 43.8 t -135.48 79.93 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.3 -0.875 . . . . 0.0 109.95 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.501 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -44.22 112.56 0.42 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.375 -0.828 . . . . 0.0 110.639 -179.663 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.6 m -73.54 -23.67 60.02 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.793 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.456 ' OD1' ' HB ' ' A' ' 8' ' ' VAL . 12.3 p-10 -160.18 -134.1 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.499 -0.751 . . . . 0.0 109.639 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' MET . . . . . 0.402 ' N ' ' CG ' ' A' ' 5' ' ' ASP . 0.0 OUTLIER -79.71 -42.47 24.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.886 -1.134 . . . . 0.0 110.131 179.81 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 8' ' ' VAL . 3.5 tp10 -121.83 -60.92 1.55 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.21 -0.931 . . . . 0.0 110.012 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.456 ' HB ' ' OD1' ' A' ' 5' ' ' ASP . 0.9 OUTLIER -42.22 126.4 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 110.072 -179.913 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.406 ' O ' HG22 ' A' ' 9' ' ' ILE . 9.9 tt -152.22 144.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.307 -0.87 . . . . 0.0 109.949 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.434 ' SG ' ' CB ' ' A' ' 14' ' ' TYR . 0.1 OUTLIER -108.78 160.11 28.51 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.168 -0.958 . . . . 0.0 110.416 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.465 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.8 Cg_endo -78.98 42.77 1.34 Allowed 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 124.119 1.589 . . . . 0.0 111.044 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.465 ' HB2' ' O ' ' A' ' 11' ' ' PRO . 10.4 m-20 63.04 137.91 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.925 -1.11 . . . . 0.0 110.248 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.67 3.46 56.18 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . 0.434 ' CB ' ' SG ' ' A' ' 10' ' ' CYS . 79.2 m-85 -125.06 165.07 18.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.196 -1.179 . . . . 0.0 110.26 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.463 ' CG2' ' HB2' ' A' ' 27' ' ' CYS . 14.7 t -115.49 143.65 45.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.27 -0.894 . . . . 0.0 110.212 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.8 m -78.03 100.47 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.376 -0.828 . . . . 0.0 110.24 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.72 132.84 53.55 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.06 145.73 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.91 . . . . 0.0 110.145 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.526 ' CB ' ' HB1' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -80.86 165.88 42.63 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.306 -0.871 . . . . 0.0 110.115 179.99 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.9 1.39 7.13 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.963 1.507 . . . . 0.0 110.798 -179.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -118.98 32.25 6.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.171 -0.956 . . . . 0.0 110.047 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.94 41.83 95.16 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.526 ' HB1' ' CB ' ' A' ' 19' ' ' LEU . . . -120.45 -178.52 3.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.29 -1.124 . . . . 0.0 110.342 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -127.11 149.7 49.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.177 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -161.48 144.56 9.92 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -94.64 132.74 39.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.152 -1.205 . . . . 0.0 110.136 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . 0.463 ' HB2' ' CG2' ' A' ' 15' ' ' THR . 13.8 m -121.75 144.99 42.06 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.118 -0.989 . . . . 0.0 110.222 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -73.45 151.48 47.84 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 123.936 1.492 . . . . 0.0 110.175 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.326 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.3 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.285 0.564 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 23.0 t -104.4 56.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 109.733 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.509 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 2.0 p-80 -47.25 128.64 12.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.396 -0.815 . . . . 0.0 110.602 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.8 m -81.93 -34.2 29.98 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.559 179.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -146.54 -60.61 0.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.447 -0.783 . . . . 0.0 110.092 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' MET . . . . . 0.52 ' HG3' ' N ' ' A' ' 7' ' ' GLU . 17.1 ptm -176.51 -36.03 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.393 -0.817 . . . . 0.0 109.809 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . 0.52 ' N ' ' HG3' ' A' ' 6' ' ' MET . 6.4 tt0 -107.05 -49.91 3.19 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.384 -0.822 . . . . 0.0 109.891 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.6 t -86.39 104.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.275 -0.891 . . . . 0.0 109.624 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.452 HD11 ' C ' ' A' ' 9' ' ' ILE . 0.0 OUTLIER -123.89 158.94 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.938 . . . . 0.0 110.216 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -120.21 156.0 55.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.155 -0.966 . . . . 0.0 109.91 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.521 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 44.1 Cg_endo -82.09 32.98 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 123.764 1.402 . . . . 0.0 111.267 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 19.1 t0 66.59 -56.31 0.4 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.101 -0.999 . . . . 0.0 111.183 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.05 -23.71 0.45 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' TYR . . . . . 0.627 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 13.7 m-85 -112.92 173.08 6.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.276 . . . . 0.0 110.913 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.442 ' O ' ' HA ' ' A' ' 26' ' ' CYS . 4.4 p -106.46 135.19 48.4 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.443 ' HA ' ' O ' ' A' ' 25' ' ' GLY . 4.0 t -88.7 104.47 16.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.926 -1.109 . . . . 0.0 111.251 -178.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.1 p -106.76 139.33 41.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.447 -0.783 . . . . 0.0 109.207 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.584 ' HG3' ' CE2' ' A' ' 24' ' ' TRP . 7.1 ttt180 -77.81 137.56 38.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.001 -1.062 . . . . 0.0 110.809 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LEU . . . . . 0.516 ' CG ' ' HD2' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -73.96 177.86 1.9 Allowed Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.51 -0.744 . . . . 0.0 109.968 179.766 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.516 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 45.7 Cg_endo -72.73 -11.12 25.75 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.931 1.49 . . . . 0.0 110.408 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.9 t -108.83 28.47 8.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.181 -0.949 . . . . 0.0 110.133 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.08 12.07 79.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . -85.62 -172.95 4.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.29 -1.123 . . . . 0.0 110.258 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.584 ' CE2' ' HG3' ' A' ' 18' ' ' ARG . 27.7 m95 -137.28 147.19 45.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.342 -0.849 . . . . 0.0 109.875 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 16' ' ' CYS . . . -143.79 151.99 23.81 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.442 ' HA ' ' O ' ' A' ' 15' ' ' THR . 7.5 m -108.58 107.02 17.35 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.298 -1.119 . . . . 0.0 110.08 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.78 132.88 23.01 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.185 -0.947 . . . . 0.0 109.945 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.525 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 44.4 Cg_endo -72.48 149.72 50.53 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 O-C-N 123.68 1.358 . . . . 0.0 110.783 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 3.0 t80 . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.386 -0.821 . . . . 0.0 110.229 -179.977 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.52 ' CG2' HD11 ' A' ' 9' ' ' ILE . 10.8 m . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.248 0.547 . . . . 0.0 110.275 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' A' ' 4' ' ' CYS . 23.4 t -99.08 82.6 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 110.086 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.511 ' ND1' ' N ' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -51.59 89.77 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 110.476 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.492 ' N ' ' O ' ' A' ' 2' ' ' VAL . 88.8 m -60.14 -19.46 53.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.91 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.461 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 1.8 t0 177.9 -170.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.517 -0.739 . . . . 0.0 109.841 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 12.5 mtt -91.75 14.08 16.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.078 -1.014 . . . . 0.0 110.436 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -127.78 3.02 6.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.886 . . . . 0.0 110.056 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.5 p -168.48 154.44 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.37 -0.831 . . . . 0.0 110.098 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.52 HD11 ' CG2' ' A' ' 1' ' ' VAL . 8.8 tt -146.39 125.52 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.921 . . . . 0.0 110.032 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.457 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 67.3 m -127.95 137.16 30.2 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.18 -0.95 . . . . 0.0 110.219 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.601 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 43.1 Cg_endo -73.06 152.88 51.73 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.838 1.441 . . . . 0.0 110.595 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.457 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 0.6 OUTLIER -37.24 -44.47 0.58 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.719 -0.613 . . . . 0.0 111.487 -179.606 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -62.58 -3.42 5.54 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.7 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . 0.601 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 17.9 m-85 -124.26 154.26 40.48 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.445 -1.621 . . . . 0.0 111.52 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.5 p -107.34 137.65 44.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.534 -0.728 . . . . 0.0 109.778 179.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.76 142.38 27.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 110.33 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.96 149.21 48.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.302 -0.873 . . . . 0.0 109.983 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.563 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -103.63 129.41 50.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.155 -0.966 . . . . 0.0 110.188 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.543 ' HB2' ' CB ' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -69.78 168.61 16.51 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 110.128 -179.94 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -74.7 2.17 6.75 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 124.009 1.531 . . . . 0.0 110.695 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -122.53 33.27 5.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.088 -1.008 . . . . 0.0 110.417 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.53 30.24 73.06 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.543 ' CB ' ' HB2' ' A' ' 19' ' ' LEU . . . -108.27 -174.14 2.45 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.248 -1.148 . . . . 0.0 110.272 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.563 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 31.7 m95 -137.84 147.88 44.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.883 . . . . 0.0 110.276 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.72 156.34 26.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.8 t -118.75 135.57 54.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -1.158 . . . . 0.0 110.527 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.61 125.49 11.99 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.32 164.81 34.23 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 123.787 1.414 . . . . 0.0 110.354 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -119.84 45.01 2.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.91 . . . . 0.0 110.222 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 p -106.76 85.26 2.13 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.252 -0.905 . . . . 0.0 110.222 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.249 179.982 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.465 HG13 HG22 ' A' ' 9' ' ' ILE . 1.4 t . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.148 0.499 . . . . 0.0 109.692 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.48 ' CG2' ' O ' ' A' ' 2' ' ' VAL . 24.9 m -112.43 80.25 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.07 -1.019 . . . . 0.0 110.108 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.409 ' C ' ' O ' ' A' ' 2' ' ' VAL . 1.4 m-70 -42.83 125.63 3.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.298 -0.876 . . . . 0.0 110.3 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -101.67 -40.0 7.19 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 110.053 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -145.46 -166.91 2.55 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.862 . . . . 0.0 110.017 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -61.21 -50.19 74.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.155 -0.966 . . . . 0.0 110.244 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.459 ' O ' ' CG ' ' A' ' 7' ' ' GLU . 0.0 OUTLIER -126.17 61.22 1.28 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 110.293 -179.824 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -167.19 119.62 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.269 -0.894 . . . . 0.0 109.696 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.48 HG22 ' N ' ' A' ' 10' ' ' CYS . 3.4 mt -131.62 162.32 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.182 -0.949 . . . . 0.0 110.666 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.508 ' SG ' ' CB ' ' A' ' 14' ' ' TYR . 0.1 OUTLIER -136.28 136.31 22.31 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.275 -0.89 . . . . 0.0 109.57 179.523 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.641 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 42.5 Cg_endo -71.27 53.79 1.7 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.753 1.396 . . . . 0.0 111.656 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.509 ' O ' ' N ' ' A' ' 14' ' ' TYR . 19.0 t0 54.12 -77.57 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.59 -0.694 . . . . 0.0 111.808 178.598 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -37.16 -28.93 0.03 OUTLIER Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . 0.641 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 24.9 m-85 -92.0 161.88 14.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.118 -1.225 . . . . 0.0 110.657 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -119.78 145.2 46.8 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.369 -0.832 . . . . 0.0 110.04 179.884 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.22 140.52 36.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -0.851 . . . . 0.0 110.358 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.62 117.14 6.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.256 -0.903 . . . . 0.0 110.119 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.416 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -72.06 149.34 44.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.121 -0.987 . . . . 0.0 109.979 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.422 ' HB2' ' HB1' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -89.36 170.4 10.84 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.188 -0.945 . . . . 0.0 110.566 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.07 -3.66 14.05 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 124.054 1.555 . . . . 0.0 110.277 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.5 m -109.33 25.64 11.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.299 -0.876 . . . . 0.0 110.038 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.39 51.54 42.28 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.422 ' HB1' ' HB2' ' A' ' 19' ' ' LEU . . . -136.95 -173.2 3.38 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.179 -1.189 . . . . 0.0 110.237 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -120.85 148.31 44.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.226 -0.921 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.74 125.52 1.82 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -96.99 130.24 44.34 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.286 -1.126 . . . . 0.0 109.716 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 95.6 m -126.88 153.11 76.14 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.149 -0.97 . . . . 0.0 110.568 -179.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.93 151.85 51.14 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.12 1.589 . . . . 0.0 110.266 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -121.17 149.12 43.28 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 110.44 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.77 82.09 1.92 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.394 -0.816 . . . . 0.0 110.031 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.6 0 O-C-N 121.297 -0.877 . . . . 0.0 110.268 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.406 HG13 HG23 ' A' ' 2' ' ' VAL . 73.1 t . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.254 0.549 . . . . 0.0 110.2 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.406 HG23 HG13 ' A' ' 1' ' ' VAL . 22.0 t -97.66 72.34 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.145 -0.972 . . . . 0.0 109.86 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.511 ' CE1' HG21 ' A' ' 9' ' ' ILE . 24.8 m-70 -46.05 106.67 0.08 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.339 -0.851 . . . . 0.0 110.668 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.475 ' HB3' ' O ' ' A' ' 8' ' ' VAL . 7.1 t -89.01 -25.64 21.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.259 -0.901 . . . . 0.0 109.632 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -156.87 -139.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.386 -0.821 . . . . 0.0 109.764 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 55.1 mtm -79.82 -50.5 10.44 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.1 -1.0 . . . . 0.0 110.023 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -122.89 -1.31 8.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.29 -0.881 . . . . 0.0 110.22 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.475 ' O ' ' HB3' ' A' ' 4' ' ' CYS . 45.0 t -89.97 75.77 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.187 -0.946 . . . . 0.0 110.252 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.511 HG21 ' CE1' ' A' ' 3' ' ' HIS . 6.8 pt -112.07 126.82 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.058 -1.026 . . . . 0.0 109.997 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -109.95 157.92 36.44 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.28 -0.887 . . . . 0.0 110.172 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.471 ' HD2' ' CD1' ' A' ' 14' ' ' TYR . 48.2 Cg_endo -81.15 41.06 1.08 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.873 1.46 . . . . 0.0 110.944 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.426 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 0.3 OUTLIER 66.34 -57.97 0.36 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.051 -1.031 . . . . 0.0 110.817 179.528 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.0 -25.02 0.59 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . 0.471 ' CD1' ' HD2' ' A' ' 11' ' ' PRO . 54.3 m-85 -96.04 163.66 13.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.035 -1.274 . . . . 0.0 110.826 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.519 ' CG2' ' O ' ' A' ' 27' ' ' CYS . 0.7 OUTLIER -113.62 131.14 56.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.473 -0.767 . . . . 0.0 109.459 179.018 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.4 t -90.54 102.38 15.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.518 -0.739 . . . . 0.0 110.373 -179.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -112.25 137.57 50.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.836 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.2 mtm105 -92.11 131.86 37.05 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 110.055 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.475 ' CG ' ' HD2' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -67.67 165.76 27.96 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.335 -0.853 . . . . 0.0 110.138 179.977 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.475 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 43.9 Cg_endo -69.62 -5.29 15.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.962 1.507 . . . . 0.0 110.325 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.15 26.99 7.03 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.413 -0.804 . . . . 0.0 110.113 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.83 27.23 72.55 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -109.38 171.0 7.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.13 -1.218 . . . . 0.0 110.389 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.1 m95 -111.2 150.51 29.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.304 -0.872 . . . . 0.0 109.864 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.76 109.27 0.41 Allowed Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.086 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -93.52 115.94 28.46 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.214 -1.168 . . . . 0.0 109.65 179.222 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.519 ' O ' ' CG2' ' A' ' 15' ' ' THR . 25.0 p -129.93 153.2 80.93 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.135 -0.978 . . . . 0.0 110.586 -179.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.82 149.84 48.64 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.045 1.55 . . . . 0.0 110.244 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 29' ' ' PHE . 72.4 t80 -147.63 59.84 1.14 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.23 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.502 ' CG2' ' O ' ' A' ' 30' ' ' THR . 15.3 t -116.18 69.92 0.75 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 110.254 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? . . . . . 0 N--CA 1.492 1.652 0 O-C-N 121.18 -0.95 . . . . 0.0 110.116 179.904 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 28.4 m . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.236 0.541 . . . . 0.0 110.327 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.499 ' HB ' ' O ' ' A' ' 10' ' ' CYS . 21.0 t -108.04 100.82 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.916 . . . . 0.0 110.117 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -81.53 89.84 6.21 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.197 -0.939 . . . . 0.0 110.105 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 44.9 m -84.74 4.45 32.69 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.21 -0.931 . . . . 0.0 110.381 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -168.88 -166.45 0.65 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.19 -0.944 . . . . 0.0 110.359 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 24.2 mtm -97.07 -27.15 14.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 110.603 -179.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -108.41 -47.83 3.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.098 -1.001 . . . . 0.0 110.769 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.484 ' C ' ' CG2' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -90.09 137.93 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.097 -1.002 . . . . 0.0 110.27 -179.821 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.484 ' CG2' ' C ' ' A' ' 8' ' ' VAL . 4.4 pt -151.2 131.19 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.258 -0.901 . . . . 0.0 110.092 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.499 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 20.5 m -122.71 162.68 37.25 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.957 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -82.93 173.34 10.27 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.736 1.388 . . . . 0.0 110.564 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -63.79 -19.22 64.83 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.288 -0.883 . . . . 0.0 111.217 -179.107 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.14 -4.91 38.39 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -132.24 175.16 9.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.032 -1.275 . . . . 0.0 110.956 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.0 p -128.56 119.01 24.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.626 -0.671 . . . . 0.0 109.331 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.419 ' O ' ' SG ' ' A' ' 16' ' ' CYS . 28.9 p -82.15 123.47 29.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.241 -0.912 . . . . 0.0 110.654 -179.287 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 m -118.05 127.4 53.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.487 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -82.37 122.68 28.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.186 -0.946 . . . . 0.0 110.331 -179.787 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.541 ' HB2' ' CB ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -67.66 170.37 7.2 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.175 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.499 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 47.9 Cg_endo -72.98 -20.02 22.5 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 O-C-N 124.049 1.552 . . . . 0.0 110.661 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.8 m -99.14 31.66 2.97 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.17 -0.956 . . . . 0.0 110.074 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.62 41.54 93.93 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.541 ' CB ' ' HB2' ' A' ' 19' ' ' LEU . . . -114.94 -172.74 2.18 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.174 -1.192 . . . . 0.0 110.336 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.487 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 20.3 m95 -140.04 147.95 41.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.927 . . . . 0.0 110.236 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 113.84 0.81 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.67 106.47 18.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -1.162 . . . . 0.0 109.993 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.8 m -119.21 139.39 27.46 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 110.232 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.47 148.22 47.86 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.017 1.535 . . . . 0.0 110.646 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 4.7 t80 -72.57 110.95 7.31 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.404 -0.81 . . . . 0.0 109.872 179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.6 t -134.27 63.07 1.63 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.285 -0.884 . . . . 0.0 110.159 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.4 mp0 . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.218 -0.926 . . . . 0.0 110.269 -179.931 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 5.5 m . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.288 0.566 . . . . 0.0 110.309 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 4' ' ' CYS . 3.1 p -122.32 88.88 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.34 -0.85 . . . . 0.0 110.059 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.508 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -59.07 82.32 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 110.429 -179.71 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.479 ' N ' ' O ' ' A' ' 2' ' ' VAL . 0.4 OUTLIER -54.13 -28.46 39.88 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.189 -0.944 . . . . 0.0 109.817 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.91 -163.79 1.86 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.356 -0.84 . . . . 0.0 109.892 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -98.96 15.57 25.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.077 -1.014 . . . . 0.0 110.601 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.479 ' HG3' ' N ' ' A' ' 8' ' ' VAL . 11.1 pt-20 -136.61 -33.16 0.8 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.102 -0.999 . . . . 0.0 110.651 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.479 ' N ' ' HG3' ' A' ' 7' ' ' GLU . 9.4 p -116.49 162.44 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.085 -1.009 . . . . 0.0 110.401 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.45 ' N ' HG23 ' A' ' 8' ' ' VAL . 3.5 tt -157.55 133.97 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.292 -0.88 . . . . 0.0 110.323 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.414 ' O ' ' CG1' ' A' ' 2' ' ' VAL . 51.2 m -107.73 144.18 28.78 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.082 -1.011 . . . . 0.0 109.589 179.489 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 13' ' ' GLY . 46.7 Cg_endo -80.33 38.01 0.72 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.675 1.355 . . . . 0.0 111.267 -179.738 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 3.0 t0 66.32 -56.33 0.38 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 110.859 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.22 -31.78 0.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . 0.515 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 47.5 m-85 -103.36 173.14 6.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.196 -1.179 . . . . 0.0 110.309 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.519 ' CG2' ' CD1' ' A' ' 29' ' ' PHE . 37.5 p -115.54 125.88 53.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.423 -0.798 . . . . 0.0 109.969 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 8.1 t -49.09 126.37 12.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 110.22 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.3 m -146.55 142.07 27.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 110.153 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.588 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -97.03 141.98 29.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 110.401 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -76.3 160.32 78.07 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 0.0 110.181 179.904 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.52 -6.97 20.06 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.985 1.518 . . . . 0.0 110.653 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.445 ' O ' ' OG ' ' A' ' 21' ' ' SER . 3.2 t -107.41 29.58 7.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 110.307 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.05 67.45 1.96 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.449 ' HB2' ' HB2' ' A' ' 19' ' ' LEU . . . -155.13 174.43 15.2 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -1.107 . . . . 0.0 110.148 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.588 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 14.6 m95 -123.06 147.63 46.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.237 -0.914 . . . . 0.0 110.252 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -165.94 155.24 26.38 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.45 ' HB3' ' HB2' ' A' ' 14' ' ' TYR . 7.8 m -98.33 125.75 43.58 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.223 -1.163 . . . . 0.0 109.862 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 1.1 m -109.61 129.45 23.91 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.156 -0.965 . . . . 0.0 110.397 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.78 155.15 54.03 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.782 1.411 . . . . 0.0 109.9 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.583 ' CE2' ' CG2' ' A' ' 30' ' ' THR . 4.6 p90 -147.66 -45.42 0.17 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.124 -0.985 . . . . 0.0 110.859 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.583 ' CG2' ' CE2' ' A' ' 29' ' ' PHE . 3.7 t -139.57 52.83 1.71 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.932 -1.105 . . . . 0.0 110.625 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 18.7 mt-30 . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.036 -1.04 . . . . 0.0 110.205 179.807 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.533 ' HB ' ' CD1' ' A' ' 9' ' ' ILE . 6.9 m . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.31 0.576 . . . . 0.0 110.22 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.53 HG21 ' CB ' ' A' ' 12' ' ' ASP . 44.6 t -105.5 103.72 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 110.292 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.405 ' C ' ' O ' ' A' ' 2' ' ' VAL . 14.2 m-70 -44.02 118.75 1.55 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.186 -0.946 . . . . 0.0 110.493 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -79.93 -37.77 33.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.322 -0.861 . . . . 0.0 109.693 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -169.54 -80.08 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.451 -0.781 . . . . 0.0 110.276 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 9.4 tpp -146.15 -53.79 0.26 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.136 -0.977 . . . . 0.0 110.59 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -102.84 13.14 35.11 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.104 -0.997 . . . . 0.0 110.205 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -138.17 141.08 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.345 -0.847 . . . . 0.0 110.08 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.533 ' CD1' ' HB ' ' A' ' 1' ' ' VAL . 0.0 OUTLIER -145.15 127.96 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 110.004 -179.825 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 14' ' ' TYR . 0.5 OUTLIER -118.65 154.85 52.74 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.053 -1.03 . . . . 0.0 110.297 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.478 ' O ' ' N ' ' A' ' 13' ' ' GLY . 48.0 Cg_endo -78.59 43.14 1.38 Allowed 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.964 1.508 . . . . 0.0 111.434 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.53 ' CB ' HG21 ' A' ' 2' ' ' VAL . 3.8 t70 65.05 -58.95 0.26 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 111.137 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.41 -26.48 0.22 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . 0.489 ' CE2' ' HB3' ' A' ' 28' ' ' PRO . 92.1 m-85 -100.87 153.43 19.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.952 -1.322 . . . . 0.0 110.955 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.521 ' CG2' ' O ' ' A' ' 27' ' ' CYS . 10.1 t -102.43 146.18 28.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 109.784 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -94.74 122.11 37.01 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.34 -0.85 . . . . 0.0 110.684 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -139.77 144.1 37.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.38 -0.825 . . . . 0.0 109.571 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.576 ' HG3' ' CH2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -92.34 134.76 34.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.511 -179.581 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.479 ' CG ' ' HD2' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -64.59 171.93 2.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.386 -0.821 . . . . 0.0 110.431 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.479 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 49.9 Cg_endo -76.2 1.55 8.17 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.062 1.559 . . . . 0.0 110.713 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 69.0 m -117.69 29.56 7.77 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.211 -0.93 . . . . 0.0 110.483 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.49 58.58 9.09 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.475 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . -145.56 168.29 20.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.299 -1.118 . . . . 0.0 109.857 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.576 ' CH2' ' HG3' ' A' ' 18' ' ' ARG . 2.0 m95 -105.14 147.6 27.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.126 -0.984 . . . . 0.0 110.203 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -154.02 133.63 4.0 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.19 128.31 48.75 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -1.157 . . . . 0.0 110.008 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.521 ' O ' ' CG2' ' A' ' 15' ' ' THR . 76.7 m -124.38 133.15 24.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 110.379 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.489 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 50.1 Cg_endo -75.48 149.8 35.28 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.867 1.456 . . . . 0.0 110.249 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.57 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 11.7 p90 -134.39 140.9 46.63 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.213 -0.93 . . . . 0.0 110.321 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 15.9 m -89.29 157.15 18.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.885 . . . . 0.0 110.097 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.211 -0.931 . . . . 0.0 110.18 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 121.348 0.594 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 89.3 t -105.96 -25.34 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.94 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 56.07 93.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.333 -0.854 . . . . 0.0 110.348 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.3 m -61.93 -36.95 82.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.915 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -163.4 -153.61 0.25 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.298 -0.876 . . . . 0.0 110.332 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -80.82 -15.74 55.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.227 -0.92 . . . . 0.0 110.619 -179.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.421 ' C ' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -135.35 23.23 3.46 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.222 -0.924 . . . . 0.0 110.514 -179.813 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.421 HG22 ' C ' ' A' ' 7' ' ' GLU . 16.6 t -142.98 149.29 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.09 -1.006 . . . . 0.0 110.254 -179.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 6.2 tt -163.04 143.22 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.228 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.421 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -119.94 168.98 9.18 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.864 . . . . 0.0 110.145 -179.918 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.47 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.3 Cg_endo -80.25 38.84 0.78 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 124.092 1.575 . . . . 0.0 111.198 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.47 ' HB2' ' O ' ' A' ' 11' ' ' PRO . 1.4 m-20 66.69 138.19 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 120.948 -1.095 . . . . 0.0 110.377 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.48 42.88 7.64 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . 0.47 ' CD1' ' HA ' ' A' ' 28' ' ' PRO . 22.0 m-85 -150.59 151.91 33.29 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.201 -1.176 . . . . 0.0 110.543 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.442 ' CG2' ' HB2' ' A' ' 27' ' ' CYS . 5.7 t -104.98 146.68 28.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.803 . . . . 0.0 110.109 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.7 m -97.83 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.305 -0.872 . . . . 0.0 110.226 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.8 m -111.0 127.15 55.43 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.194 -0.941 . . . . 0.0 110.152 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.556 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -85.69 124.79 32.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.121 -0.987 . . . . 0.0 110.435 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.453 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -72.0 161.73 77.24 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.29 -0.881 . . . . 0.0 110.054 179.924 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -74.16 -5.83 17.56 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.951 1.501 . . . . 0.0 110.548 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 t -111.56 31.81 5.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.27 -0.894 . . . . 0.0 110.246 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.67 68.75 1.55 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.453 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -155.58 179.6 9.03 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.317 -1.108 . . . . 0.0 110.182 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.556 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 24.8 m95 -134.57 147.27 50.23 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -0.865 . . . . 0.0 110.18 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.8 133.31 6.31 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -97.25 112.56 24.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -1.166 . . . . 0.0 110.29 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.442 ' HB2' ' CG2' ' A' ' 15' ' ' THR . 1.3 m -105.56 144.43 28.83 Favored Pre-proline 0 N--CA 1.493 1.675 0 O-C-N 121.309 -0.869 . . . . 0.0 110.067 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HA ' ' CD1' ' A' ' 14' ' ' TYR . 44.0 Cg_endo -70.92 149.08 58.92 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.805 1.424 . . . . 0.0 110.717 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -153.6 20.56 0.54 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 110.328 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 34.6 p -103.88 31.17 4.64 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.186 -0.946 . . . . 0.0 110.409 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.9 pt20 . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.169 -0.957 . . . . 0.0 110.182 -179.995 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 20.0 m . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.202 0.525 . . . . 0.0 110.271 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . 0.451 HG13 ' N ' ' A' ' 3' ' ' HIS . 85.4 t -107.69 146.78 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.298 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.451 ' N ' HG13 ' A' ' 2' ' ' VAL . 10.9 t60 -70.56 80.78 0.58 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.2 -0.938 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.479 ' HB3' ' HB ' ' A' ' 8' ' ' VAL . 3.7 t -40.8 -52.98 2.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.395 -0.816 . . . . 0.0 110.536 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 1.2 t0 -145.46 -147.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.125 -0.985 . . . . 0.0 110.288 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -78.04 -33.81 50.82 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.227 -0.92 . . . . 0.0 110.444 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -126.93 20.47 7.0 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.107 -0.996 . . . . 0.0 110.471 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.479 ' HB ' ' HB3' ' A' ' 4' ' ' CYS . 16.3 t -126.8 152.52 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.282 -0.886 . . . . 0.0 109.931 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.458 ' CG2' ' O ' ' A' ' 9' ' ' ILE . 0.7 OUTLIER -146.04 105.82 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.095 -1.003 . . . . 0.0 110.825 -179.619 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.45 ' O ' ' N ' ' A' ' 2' ' ' VAL . 84.1 m -121.07 161.19 41.82 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.267 -0.895 . . . . 0.0 109.546 179.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.585 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 40.5 Cg_endo -72.71 154.99 54.49 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.787 1.414 . . . . 0.0 110.881 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -48.86 -19.16 0.35 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.564 -0.71 . . . . 0.0 111.544 -178.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.431 ' O ' ' CD1' ' A' ' 14' ' ' TYR . . . -87.24 32.27 4.17 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . 0.585 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 11.6 m-85 -140.78 162.35 35.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.064 -1.257 . . . . 0.0 110.833 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.514 ' CG2' ' O ' ' A' ' 27' ' ' CYS . 1.0 OUTLIER -128.99 118.27 22.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.519 -0.738 . . . . 0.0 109.419 179.482 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 130.44 40.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.375 -0.828 . . . . 0.0 110.863 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -144.02 131.17 20.65 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.704 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.4 132.26 35.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 110.21 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.468 ' HB2' ' CB ' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -62.98 165.35 10.37 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.337 -0.852 . . . . 0.0 110.093 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -80.01 41.58 1.15 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.955 1.503 . . . . 0.0 110.848 179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -168.33 30.05 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.029 -1.044 . . . . 0.0 110.488 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.78 61.47 3.09 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.468 ' CB ' ' HB2' ' A' ' 19' ' ' LEU . . . -151.41 170.68 18.98 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.314 -1.109 . . . . 0.0 110.097 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.433 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 1.7 m95 -116.19 149.22 39.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.139 -0.975 . . . . 0.0 110.466 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.76 123.57 1.03 Allowed Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 15' ' ' THR . 26.3 p -97.28 130.09 44.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 110.235 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.514 ' O ' ' CG2' ' A' ' 15' ' ' THR . 0.0 OUTLIER -100.0 150.07 36.55 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.26 -0.9 . . . . 0.0 109.906 179.851 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.97 145.89 63.25 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.797 1.42 . . . . 0.0 110.58 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -87.83 119.81 28.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.528 -0.733 . . . . 0.0 109.982 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.2 t -143.26 37.65 1.39 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.296 -0.878 . . . . 0.0 110.169 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.262 -0.899 . . . . 0.0 110.062 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 17.1 m . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.16 0.505 . . . . 0.0 110.236 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 43.8 t -135.48 79.93 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.3 -0.875 . . . . 0.0 109.95 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.501 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -44.22 112.56 0.42 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.375 -0.828 . . . . 0.0 110.639 -179.663 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.6 m -73.54 -23.67 60.02 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.793 179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.456 ' OD1' ' HB ' ' A' ' 8' ' ' VAL . 12.3 p-10 -160.18 -134.1 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.499 -0.751 . . . . 0.0 109.639 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' MET . . . . . 0.402 ' N ' ' CG ' ' A' ' 5' ' ' ASP . 0.0 OUTLIER -79.71 -42.47 24.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.886 -1.134 . . . . 0.0 110.131 179.81 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 8' ' ' VAL . 3.5 tp10 -121.83 -60.92 1.55 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.21 -0.931 . . . . 0.0 110.012 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.456 ' HB ' ' OD1' ' A' ' 5' ' ' ASP . 0.9 OUTLIER -42.22 126.4 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 110.072 -179.913 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.406 ' O ' HG22 ' A' ' 9' ' ' ILE . 9.9 tt -152.22 144.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.307 -0.87 . . . . 0.0 109.949 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.434 ' SG ' ' CB ' ' A' ' 14' ' ' TYR . 0.1 OUTLIER -108.78 160.11 28.51 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.168 -0.958 . . . . 0.0 110.416 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.465 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.8 Cg_endo -78.98 42.77 1.34 Allowed 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 124.119 1.589 . . . . 0.0 111.044 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.465 ' HB2' ' O ' ' A' ' 11' ' ' PRO . 10.4 m-20 63.04 137.91 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.925 -1.11 . . . . 0.0 110.248 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.67 3.46 56.18 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . 0.434 ' CB ' ' SG ' ' A' ' 10' ' ' CYS . 79.2 m-85 -125.06 165.07 18.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.196 -1.179 . . . . 0.0 110.26 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.463 ' CG2' ' HB2' ' A' ' 27' ' ' CYS . 14.7 t -115.49 143.65 45.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.27 -0.894 . . . . 0.0 110.212 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.8 m -78.03 100.47 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.376 -0.828 . . . . 0.0 110.24 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.72 132.84 53.55 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.06 145.73 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.91 . . . . 0.0 110.145 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.526 ' CB ' ' HB1' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -80.86 165.88 42.63 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.306 -0.871 . . . . 0.0 110.115 179.99 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.9 1.39 7.13 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.963 1.507 . . . . 0.0 110.798 -179.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -118.98 32.25 6.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.171 -0.956 . . . . 0.0 110.047 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.94 41.83 95.16 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.526 ' HB1' ' CB ' ' A' ' 19' ' ' LEU . . . -120.45 -178.52 3.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.29 -1.124 . . . . 0.0 110.342 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -127.11 149.7 49.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.177 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -161.48 144.56 9.92 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -94.64 132.74 39.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.152 -1.205 . . . . 0.0 110.136 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . 0.463 ' HB2' ' CG2' ' A' ' 15' ' ' THR . 13.8 m -121.75 144.99 42.06 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.118 -0.989 . . . . 0.0 110.222 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -73.45 151.48 47.84 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 123.936 1.492 . . . . 0.0 110.175 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -158.53 53.74 0.43 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.326 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.0 t -114.14 31.4 6.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.37 -0.831 . . . . 0.0 109.95 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 10.4 mm-40 . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.916 . . . . 0.0 110.225 -179.935 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.3 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.285 0.564 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 23.0 t -104.4 56.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 109.733 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.509 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 2.0 p-80 -47.25 128.64 12.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.396 -0.815 . . . . 0.0 110.602 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.8 m -81.93 -34.2 29.98 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.559 179.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -146.54 -60.61 0.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.447 -0.783 . . . . 0.0 110.092 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' MET . . . . . 0.52 ' HG3' ' N ' ' A' ' 7' ' ' GLU . 17.1 ptm -176.51 -36.03 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.393 -0.817 . . . . 0.0 109.809 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.52 ' N ' ' HG3' ' A' ' 6' ' ' MET . 6.4 tt0 -107.05 -49.91 3.19 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.384 -0.822 . . . . 0.0 109.891 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.6 t -86.39 104.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.275 -0.891 . . . . 0.0 109.624 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.452 HD11 ' C ' ' A' ' 9' ' ' ILE . 0.0 OUTLIER -123.89 158.94 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.938 . . . . 0.0 110.216 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -120.21 156.0 55.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.155 -0.966 . . . . 0.0 109.91 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.521 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 44.1 Cg_endo -82.09 32.98 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 123.764 1.402 . . . . 0.0 111.267 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 19.1 t0 66.59 -56.31 0.4 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.101 -0.999 . . . . 0.0 111.183 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.05 -23.71 0.45 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' TYR . . . . . 0.627 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 13.7 m-85 -112.92 173.08 6.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.276 . . . . 0.0 110.913 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.442 ' O ' ' HA ' ' A' ' 26' ' ' CYS . 4.4 p -106.46 135.19 48.4 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.443 ' HA ' ' O ' ' A' ' 25' ' ' GLY . 4.0 t -88.7 104.47 16.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.926 -1.109 . . . . 0.0 111.251 -178.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.1 p -106.76 139.33 41.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.447 -0.783 . . . . 0.0 109.207 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.584 ' HG3' ' CE2' ' A' ' 24' ' ' TRP . 7.1 ttt180 -77.81 137.56 38.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.001 -1.062 . . . . 0.0 110.809 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . 0.516 ' CG ' ' HD2' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -73.96 177.86 1.9 Allowed Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.51 -0.744 . . . . 0.0 109.968 179.766 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.516 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 45.7 Cg_endo -72.73 -11.12 25.75 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.931 1.49 . . . . 0.0 110.408 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.9 t -108.83 28.47 8.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.181 -0.949 . . . . 0.0 110.133 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.08 12.07 79.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . -85.62 -172.95 4.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.29 -1.123 . . . . 0.0 110.258 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.584 ' CE2' ' HG3' ' A' ' 18' ' ' ARG . 27.7 m95 -137.28 147.19 45.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.342 -0.849 . . . . 0.0 109.875 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.443 ' O ' ' HA ' ' A' ' 16' ' ' CYS . . . -143.79 151.99 23.81 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.442 ' HA ' ' O ' ' A' ' 15' ' ' THR . 7.5 m -108.58 107.02 17.35 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.298 -1.119 . . . . 0.0 110.08 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.78 132.88 23.01 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.185 -0.947 . . . . 0.0 109.945 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.525 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 44.4 Cg_endo -72.48 149.72 50.53 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 O-C-N 123.68 1.358 . . . . 0.0 110.783 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -117.1 99.41 7.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.386 -0.821 . . . . 0.0 110.229 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . 0.413 ' O ' ' CG2' ' A' ' 30' ' ' THR . 6.1 t -144.41 101.17 3.65 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.282 -0.886 . . . . 0.0 110.013 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 9.6 mm100 . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.276 -0.89 . . . . 0.0 110.189 -179.799 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.925 HG21 HD11 ' A' ' 9' ' ' ILE . 10.8 m . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.248 0.547 . . . . 0.0 110.275 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' A' ' 4' ' ' CYS . 23.4 t -99.08 82.6 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 110.086 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.511 ' ND1' ' N ' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -51.59 89.77 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 110.476 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.492 ' N ' ' O ' ' A' ' 2' ' ' VAL . 88.8 m -60.14 -19.46 53.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.91 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.451 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 1.8 t0 177.9 -170.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.517 -0.739 . . . . 0.0 109.841 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 12.5 mtt -91.75 14.08 16.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.078 -1.014 . . . . 0.0 110.436 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -127.78 3.02 6.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.886 . . . . 0.0 110.056 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.425 HG13 ' HB2' ' A' ' 4' ' ' CYS . 8.5 p -168.48 154.44 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.37 -0.831 . . . . 0.0 110.098 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.925 HD11 HG21 ' A' ' 1' ' ' VAL . 8.8 tt -146.39 125.52 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.921 . . . . 0.0 110.032 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.461 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 67.3 m -127.95 137.16 30.2 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.18 -0.95 . . . . 0.0 110.219 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.614 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 43.1 Cg_endo -73.06 152.88 51.73 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.838 1.441 . . . . 0.0 110.595 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.457 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 0.6 OUTLIER -37.24 -44.47 0.58 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.719 -0.613 . . . . 0.0 111.487 -179.606 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -62.58 -3.42 5.54 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.7 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' TYR . . . . . 0.614 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 17.9 m-85 -124.26 154.26 40.48 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.445 -1.621 . . . . 0.0 111.52 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.5 p -107.34 137.65 44.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.534 -0.728 . . . . 0.0 109.778 179.639 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.76 142.38 27.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 110.33 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.96 149.21 48.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.302 -0.873 . . . . 0.0 109.983 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.589 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -103.63 129.41 50.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.155 -0.966 . . . . 0.0 110.188 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.974 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -69.78 168.61 16.51 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 110.128 -179.94 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.59 ' HD2' HD23 ' A' ' 19' ' ' LEU . 46.6 Cg_endo -74.7 2.17 6.75 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 124.009 1.531 . . . . 0.0 110.695 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -122.53 33.27 5.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.088 -1.008 . . . . 0.0 110.417 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.53 30.24 73.06 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.974 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -108.27 -174.14 2.45 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.248 -1.148 . . . . 0.0 110.272 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.589 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 31.7 m95 -137.84 147.88 44.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.883 . . . . 0.0 110.276 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.72 156.34 26.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.8 t -118.75 135.57 54.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -1.158 . . . . 0.0 110.527 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.61 125.49 11.99 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.32 164.81 34.23 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 123.787 1.414 . . . . 0.0 110.354 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.91 . . . . 0.0 110.222 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.597 HG12 ' H ' ' A' ' 2' ' ' VAL . 1.4 t . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.148 0.499 . . . . 0.0 109.692 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.761 HG22 ' O ' ' A' ' 10' ' ' CYS . 24.9 m -112.43 80.25 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.07 -1.019 . . . . 0.0 110.108 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.409 ' C ' ' O ' ' A' ' 2' ' ' VAL . 1.4 m-70 -42.83 125.63 3.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.298 -0.876 . . . . 0.0 110.3 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.414 ' HB3' HG12 ' A' ' 8' ' ' VAL . 0.1 OUTLIER -101.67 -40.0 7.19 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 110.053 179.667 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -145.46 -166.91 2.55 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.862 . . . . 0.0 110.017 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -61.21 -50.19 74.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.155 -0.966 . . . . 0.0 110.244 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.582 ' O ' HG23 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -126.17 61.22 1.28 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 110.293 -179.824 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 7' ' ' GLU . 1.0 OUTLIER -167.19 119.62 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.269 -0.894 . . . . 0.0 109.696 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 10' ' ' CYS . 3.4 mt -131.62 162.32 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.182 -0.949 . . . . 0.0 110.666 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.761 ' O ' HG22 ' A' ' 2' ' ' VAL . 0.1 OUTLIER -136.28 136.31 22.31 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.275 -0.89 . . . . 0.0 109.57 179.523 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.66 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 42.5 Cg_endo -71.27 53.79 1.7 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.753 1.396 . . . . 0.0 111.656 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.509 ' O ' ' N ' ' A' ' 14' ' ' TYR . 19.0 t0 54.12 -77.57 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.59 -0.694 . . . . 0.0 111.808 178.598 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -37.16 -28.93 0.03 OUTLIER Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' TYR . . . . . 0.66 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 24.9 m-85 -92.0 161.88 14.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.118 -1.225 . . . . 0.0 110.657 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.514 HG22 ' O ' ' A' ' 27' ' ' CYS . 0.6 OUTLIER -119.78 145.2 46.8 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.369 -0.832 . . . . 0.0 110.04 179.884 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.22 140.52 36.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -0.851 . . . . 0.0 110.358 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.62 117.14 6.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.256 -0.903 . . . . 0.0 110.119 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -72.06 149.34 44.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.121 -0.987 . . . . 0.0 109.979 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.513 HD23 ' HD2' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -89.36 170.4 10.84 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.188 -0.945 . . . . 0.0 110.566 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.513 ' HD2' HD23 ' A' ' 19' ' ' LEU . 46.3 Cg_endo -73.07 -3.66 14.05 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 124.054 1.555 . . . . 0.0 110.277 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.5 m -109.33 25.64 11.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.299 -0.876 . . . . 0.0 110.038 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.39 51.54 42.28 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.508 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -136.95 -173.2 3.38 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.179 -1.189 . . . . 0.0 110.237 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -120.85 148.31 44.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.226 -0.921 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.74 125.52 1.82 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -96.99 130.24 44.34 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.286 -1.126 . . . . 0.0 109.716 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.514 ' O ' HG22 ' A' ' 15' ' ' THR . 95.6 m -126.88 153.11 76.14 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.149 -0.97 . . . . 0.0 110.568 -179.623 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.93 151.85 51.14 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.12 1.589 . . . . 0.0 110.266 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 110.44 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.569 HG12 HG23 ' A' ' 2' ' ' VAL . 73.1 t . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.254 0.549 . . . . 0.0 110.2 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.569 HG23 HG12 ' A' ' 1' ' ' VAL . 22.0 t -97.66 72.34 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.145 -0.972 . . . . 0.0 109.86 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.502 ' CE1' HG21 ' A' ' 9' ' ' ILE . 24.8 m-70 -46.05 106.67 0.08 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.339 -0.851 . . . . 0.0 110.668 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.497 ' HB3' ' O ' ' A' ' 8' ' ' VAL . 7.1 t -89.01 -25.64 21.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.259 -0.901 . . . . 0.0 109.632 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -156.87 -139.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.386 -0.821 . . . . 0.0 109.764 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 55.1 mtm -79.82 -50.5 10.44 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.1 -1.0 . . . . 0.0 110.023 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -122.89 -1.31 8.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.29 -0.881 . . . . 0.0 110.22 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.497 ' O ' ' HB3' ' A' ' 4' ' ' CYS . 45.0 t -89.97 75.77 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.187 -0.946 . . . . 0.0 110.252 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.502 HG21 ' CE1' ' A' ' 3' ' ' HIS . 6.8 pt -112.07 126.82 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.058 -1.026 . . . . 0.0 109.997 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -109.95 157.92 36.44 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.28 -0.887 . . . . 0.0 110.172 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.473 ' O ' ' N ' ' A' ' 13' ' ' GLY . 48.2 Cg_endo -81.15 41.06 1.08 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.873 1.46 . . . . 0.0 110.944 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.54 ' OD1' HG21 ' A' ' 2' ' ' VAL . 0.3 OUTLIER 66.34 -57.97 0.36 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.051 -1.031 . . . . 0.0 110.817 179.528 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.473 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.0 -25.02 0.59 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' TYR . . . . . 0.469 ' CD1' ' HD2' ' A' ' 11' ' ' PRO . 54.3 m-85 -96.04 163.66 13.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.035 -1.274 . . . . 0.0 110.826 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.749 HG22 ' O ' ' A' ' 27' ' ' CYS . 0.7 OUTLIER -113.62 131.14 56.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.473 -0.767 . . . . 0.0 109.459 179.018 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.4 t -90.54 102.38 15.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.518 -0.739 . . . . 0.0 110.373 -179.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -112.25 137.57 50.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.836 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.2 mtm105 -92.11 131.86 37.05 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 110.055 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.587 HD23 ' HD2' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -67.67 165.76 27.96 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.335 -0.853 . . . . 0.0 110.138 179.977 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.587 ' HD2' HD23 ' A' ' 19' ' ' LEU . 43.9 Cg_endo -69.62 -5.29 15.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.962 1.507 . . . . 0.0 110.325 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.15 26.99 7.03 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.413 -0.804 . . . . 0.0 110.113 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.83 27.23 72.55 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -109.38 171.0 7.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.13 -1.218 . . . . 0.0 110.389 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.1 m95 -111.2 150.51 29.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.304 -0.872 . . . . 0.0 109.864 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.76 109.27 0.41 Allowed Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.086 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -93.52 115.94 28.46 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.214 -1.168 . . . . 0.0 109.65 179.222 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.749 ' O ' HG22 ' A' ' 15' ' ' THR . 25.0 p -129.93 153.2 80.93 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.135 -0.978 . . . . 0.0 110.586 -179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.82 149.84 48.64 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.045 1.55 . . . . 0.0 110.244 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 29' ' ' PHE . 72.4 t80 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.23 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.421 HG13 ' H3 ' ' A' ' 1' ' ' VAL . 28.4 m . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.236 0.541 . . . . 0.0 110.327 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.507 ' HB ' ' O ' ' A' ' 10' ' ' CYS . 21.0 t -108.04 100.82 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.916 . . . . 0.0 110.117 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -81.53 89.84 6.21 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.197 -0.939 . . . . 0.0 110.105 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 44.9 m -84.74 4.45 32.69 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.21 -0.931 . . . . 0.0 110.381 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -168.88 -166.45 0.65 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.19 -0.944 . . . . 0.0 110.359 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 24.2 mtm -97.07 -27.15 14.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 110.603 -179.688 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -108.41 -47.83 3.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.098 -1.001 . . . . 0.0 110.769 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.484 ' C ' ' CG2' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -90.09 137.93 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.097 -1.002 . . . . 0.0 110.27 -179.821 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.484 ' CG2' ' C ' ' A' ' 8' ' ' VAL . 4.4 pt -151.2 131.19 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.258 -0.901 . . . . 0.0 110.092 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.507 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 20.5 m -122.71 162.68 37.25 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.957 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -82.93 173.34 10.27 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.736 1.388 . . . . 0.0 110.564 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -63.79 -19.22 64.83 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.288 -0.883 . . . . 0.0 111.217 -179.107 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.14 -4.91 38.39 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -132.24 175.16 9.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.032 -1.275 . . . . 0.0 110.956 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.0 p -128.56 119.01 24.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.626 -0.671 . . . . 0.0 109.331 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.419 ' O ' ' SG ' ' A' ' 16' ' ' CYS . 28.9 p -82.15 123.47 29.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.241 -0.912 . . . . 0.0 110.654 -179.287 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 m -118.05 127.4 53.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.506 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -82.37 122.68 28.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.186 -0.946 . . . . 0.0 110.331 -179.787 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 1.019 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -67.66 170.37 7.2 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.175 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.523 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 47.9 Cg_endo -72.98 -20.02 22.5 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 O-C-N 124.049 1.552 . . . . 0.0 110.661 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.8 m -99.14 31.66 2.97 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.17 -0.956 . . . . 0.0 110.074 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.62 41.54 93.93 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 1.019 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -114.94 -172.74 2.18 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.174 -1.192 . . . . 0.0 110.336 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.506 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 20.3 m95 -140.04 147.95 41.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.927 . . . . 0.0 110.236 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 113.84 0.81 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.67 106.47 18.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -1.162 . . . . 0.0 109.993 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.8 m -119.21 139.39 27.46 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 110.232 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.47 148.22 47.86 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.017 1.535 . . . . 0.0 110.646 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 4.7 t80 . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.404 -0.81 . . . . 0.0 109.872 179.854 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.869 ' CG2' HD11 ' A' ' 9' ' ' ILE . 5.5 m . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.288 0.566 . . . . 0.0 110.309 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.831 HG12 ' O ' ' A' ' 10' ' ' CYS . 3.1 p -122.32 88.88 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.34 -0.85 . . . . 0.0 110.059 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.508 ' ND1' ' O ' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -59.07 82.32 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 110.429 -179.71 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.479 ' N ' ' O ' ' A' ' 2' ' ' VAL . 0.4 OUTLIER -54.13 -28.46 39.88 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.189 -0.944 . . . . 0.0 109.817 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.91 -163.79 1.86 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.356 -0.84 . . . . 0.0 109.892 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -98.96 15.57 25.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.077 -1.014 . . . . 0.0 110.601 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.492 ' HG3' ' N ' ' A' ' 8' ' ' VAL . 11.1 pt-20 -136.61 -33.16 0.8 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.102 -0.999 . . . . 0.0 110.651 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.492 ' N ' ' HG3' ' A' ' 7' ' ' GLU . 9.4 p -116.49 162.44 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.085 -1.009 . . . . 0.0 110.401 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.869 HD11 ' CG2' ' A' ' 1' ' ' VAL . 3.5 tt -157.55 133.97 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.292 -0.88 . . . . 0.0 110.323 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.831 ' O ' HG12 ' A' ' 2' ' ' VAL . 51.2 m -107.73 144.18 28.78 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.082 -1.011 . . . . 0.0 109.589 179.489 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 13' ' ' GLY . 46.7 Cg_endo -80.33 38.01 0.72 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.675 1.355 . . . . 0.0 111.267 -179.738 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 3.0 t0 66.32 -56.33 0.38 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 110.859 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.22 -31.78 0.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' TYR . . . . . 0.515 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 47.5 m-85 -103.36 173.14 6.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.196 -1.179 . . . . 0.0 110.309 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.595 HG23 ' CD1' ' A' ' 29' ' ' PHE . 37.5 p -115.54 125.88 53.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.423 -0.798 . . . . 0.0 109.969 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 8.1 t -49.09 126.37 12.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 110.22 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.3 m -146.55 142.07 27.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 110.153 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.611 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -97.03 141.98 29.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 110.401 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.755 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -76.3 160.32 78.07 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 0.0 110.181 179.904 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.52 -6.97 20.06 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.985 1.518 . . . . 0.0 110.653 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 t -107.41 29.58 7.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 110.307 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.05 67.45 1.96 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.755 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -155.13 174.43 15.2 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -1.107 . . . . 0.0 110.148 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.611 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 14.6 m95 -123.06 147.63 46.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.237 -0.914 . . . . 0.0 110.252 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -165.94 155.24 26.38 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.496 ' HB3' ' HB2' ' A' ' 14' ' ' TYR . 7.8 m -98.33 125.75 43.58 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.223 -1.163 . . . . 0.0 109.862 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 1.1 m -109.61 129.45 23.91 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.156 -0.965 . . . . 0.0 110.397 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.78 155.15 54.03 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.782 1.411 . . . . 0.0 109.9 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.595 ' CD1' HG23 ' A' ' 15' ' ' THR . 4.6 p90 . . . . . 0 N--CA 1.49 1.573 0 O-C-N 121.124 -0.985 . . . . 0.0 110.859 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.545 ' HB ' ' CD1' ' A' ' 9' ' ' ILE . 6.9 m . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.31 0.576 . . . . 0.0 110.22 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.55 HG21 ' OD2' ' A' ' 12' ' ' ASP . 44.6 t -105.5 103.72 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 110.292 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.405 ' C ' ' O ' ' A' ' 2' ' ' VAL . 14.2 m-70 -44.02 118.75 1.55 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.186 -0.946 . . . . 0.0 110.493 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -79.93 -37.77 33.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.322 -0.861 . . . . 0.0 109.693 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -169.54 -80.08 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.451 -0.781 . . . . 0.0 110.276 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 9.4 tpp -146.15 -53.79 0.26 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.136 -0.977 . . . . 0.0 110.59 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -102.84 13.14 35.11 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.104 -0.997 . . . . 0.0 110.205 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -138.17 141.08 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.345 -0.847 . . . . 0.0 110.08 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.545 ' CD1' ' HB ' ' A' ' 1' ' ' VAL . 0.0 OUTLIER -145.15 127.96 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 110.004 -179.825 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.465 ' SG ' ' HB2' ' A' ' 14' ' ' TYR . 0.5 OUTLIER -118.65 154.85 52.74 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.053 -1.03 . . . . 0.0 110.297 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.478 ' O ' ' N ' ' A' ' 13' ' ' GLY . 48.0 Cg_endo -78.59 43.14 1.38 Allowed 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.964 1.508 . . . . 0.0 111.434 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.55 ' OD2' HG21 ' A' ' 2' ' ' VAL . 3.8 t70 65.05 -58.95 0.26 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 111.137 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.41 -26.48 0.22 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 28' ' ' PRO . 92.1 m-85 -100.87 153.43 19.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.952 -1.322 . . . . 0.0 110.955 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . 1.081 HG22 ' O ' ' A' ' 27' ' ' CYS . 10.1 t -102.43 146.18 28.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 109.784 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -94.74 122.11 37.01 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.34 -0.85 . . . . 0.0 110.684 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -139.77 144.1 37.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.38 -0.825 . . . . 0.0 109.571 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.594 ' HG3' ' CH2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -92.34 134.76 34.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.511 -179.581 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.504 ' CG ' ' HD2' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -64.59 171.93 2.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.386 -0.821 . . . . 0.0 110.431 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.504 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 49.9 Cg_endo -76.2 1.55 8.17 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.062 1.559 . . . . 0.0 110.713 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 69.0 m -117.69 29.56 7.77 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.211 -0.93 . . . . 0.0 110.483 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.49 58.58 9.09 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.51 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . -145.56 168.29 20.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.299 -1.118 . . . . 0.0 109.857 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.594 ' CH2' ' HG3' ' A' ' 18' ' ' ARG . 2.0 m95 -105.14 147.6 27.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.126 -0.984 . . . . 0.0 110.203 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -154.02 133.63 4.0 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.19 128.31 48.75 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -1.157 . . . . 0.0 110.008 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 1.081 ' O ' HG22 ' A' ' 15' ' ' THR . 76.7 m -124.38 133.15 24.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 110.379 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.479 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 50.1 Cg_endo -75.48 149.8 35.28 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.867 1.456 . . . . 0.0 110.249 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.57 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 11.7 p90 . . . . . 0 N--CA 1.493 1.702 0 O-C-N 121.213 -0.93 . . . . 0.0 110.321 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 121.348 0.594 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 89.3 t -105.96 -25.34 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.94 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 56.07 93.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.333 -0.854 . . . . 0.0 110.348 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.3 m -61.93 -36.95 82.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.915 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -163.4 -153.61 0.25 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.298 -0.876 . . . . 0.0 110.332 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -80.82 -15.74 55.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.227 -0.92 . . . . 0.0 110.619 -179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -135.35 23.23 3.46 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.222 -0.924 . . . . 0.0 110.514 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 16.6 t -142.98 149.29 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.09 -1.006 . . . . 0.0 110.254 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 6.2 tt -163.04 143.22 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.228 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.449 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -119.94 168.98 9.18 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.864 . . . . 0.0 110.145 -179.918 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.3 Cg_endo -80.25 38.84 0.78 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 124.092 1.575 . . . . 0.0 111.198 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.456 ' HB2' ' O ' ' A' ' 11' ' ' PRO . 1.4 m-20 66.69 138.19 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 120.948 -1.095 . . . . 0.0 110.377 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.48 42.88 7.64 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' TYR . . . . . 0.421 ' CD1' ' HA ' ' A' ' 28' ' ' PRO . 22.0 m-85 -150.59 151.91 33.29 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.201 -1.176 . . . . 0.0 110.543 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.755 HG22 ' O ' ' A' ' 27' ' ' CYS . 5.7 t -104.98 146.68 28.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.803 . . . . 0.0 110.109 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.7 m -97.83 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.305 -0.872 . . . . 0.0 110.226 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.8 m -111.0 127.15 55.43 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.194 -0.941 . . . . 0.0 110.152 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.581 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -85.69 124.79 32.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.121 -0.987 . . . . 0.0 110.435 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.808 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -72.0 161.73 77.24 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.29 -0.881 . . . . 0.0 110.054 179.924 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -74.16 -5.83 17.56 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.951 1.501 . . . . 0.0 110.548 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 t -111.56 31.81 5.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.27 -0.894 . . . . 0.0 110.246 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.67 68.75 1.55 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.808 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -155.58 179.6 9.03 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.317 -1.108 . . . . 0.0 110.182 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 24.8 m95 -134.57 147.27 50.23 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -0.865 . . . . 0.0 110.18 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.8 133.31 6.31 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -97.25 112.56 24.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -1.166 . . . . 0.0 110.29 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.755 ' O ' HG22 ' A' ' 15' ' ' THR . 1.3 m -105.56 144.43 28.83 Favored Pre-proline 0 N--CA 1.493 1.675 0 O-C-N 121.309 -0.869 . . . . 0.0 110.067 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' CD1' ' A' ' 14' ' ' TYR . 44.0 Cg_endo -70.92 149.08 58.92 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.805 1.424 . . . . 0.0 110.717 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 1.8 t80 . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 110.328 -179.93 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.403 HG23 HD11 ' A' ' 9' ' ' ILE . 20.0 m . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.202 0.525 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 85.4 t -107.69 146.78 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.298 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.434 ' O ' ' C ' ' A' ' 4' ' ' CYS . 10.9 t60 -70.56 80.78 0.58 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.2 -0.938 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.49 ' HB3' ' HB ' ' A' ' 8' ' ' VAL . 3.7 t -40.8 -52.98 2.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.395 -0.816 . . . . 0.0 110.536 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 1.2 t0 -145.46 -147.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.125 -0.985 . . . . 0.0 110.288 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -78.04 -33.81 50.82 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.227 -0.92 . . . . 0.0 110.444 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -126.93 20.47 7.0 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.107 -0.996 . . . . 0.0 110.471 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.49 ' HB ' ' HB3' ' A' ' 4' ' ' CYS . 16.3 t -126.8 152.52 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.282 -0.886 . . . . 0.0 109.931 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 9' ' ' ILE . 0.7 OUTLIER -146.04 105.82 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.095 -1.003 . . . . 0.0 110.825 -179.619 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 84.1 m -121.07 161.19 41.82 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.267 -0.895 . . . . 0.0 109.546 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.599 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 40.5 Cg_endo -72.71 154.99 54.49 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.787 1.414 . . . . 0.0 110.881 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -48.86 -19.16 0.35 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.564 -0.71 . . . . 0.0 111.544 -178.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.431 ' O ' ' CD1' ' A' ' 14' ' ' TYR . . . -87.24 32.27 4.17 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' TYR . . . . . 0.599 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 11.6 m-85 -140.78 162.35 35.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.064 -1.257 . . . . 0.0 110.833 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.924 HG22 ' O ' ' A' ' 27' ' ' CYS . 1.0 OUTLIER -128.99 118.27 22.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.519 -0.738 . . . . 0.0 109.419 179.482 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 130.44 40.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.375 -0.828 . . . . 0.0 110.863 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -144.02 131.17 20.65 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.704 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.41 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -81.4 132.26 35.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 110.21 -179.817 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.903 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -62.98 165.35 10.37 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.337 -0.852 . . . . 0.0 110.093 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.489 ' HD2' HD23 ' A' ' 19' ' ' LEU . 50.0 Cg_endo -80.01 41.58 1.15 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.955 1.503 . . . . 0.0 110.848 179.76 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -168.33 30.05 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.029 -1.044 . . . . 0.0 110.488 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.78 61.47 3.09 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.903 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -151.41 170.68 18.98 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.314 -1.109 . . . . 0.0 110.097 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.421 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 1.7 m95 -116.19 149.22 39.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.139 -0.975 . . . . 0.0 110.466 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.76 123.57 1.03 Allowed Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 15' ' ' THR . 26.3 p -97.28 130.09 44.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 110.235 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.924 ' O ' HG22 ' A' ' 15' ' ' THR . 0.0 OUTLIER -100.0 150.07 36.55 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.26 -0.9 . . . . 0.0 109.906 179.851 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.97 145.89 63.25 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.797 1.42 . . . . 0.0 110.58 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.528 -0.733 . . . . 0.0 109.982 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.501 ' HB ' HD11 ' A' ' 9' ' ' ILE . 17.1 m . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.16 0.505 . . . . 0.0 110.236 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' VAL . . . . . 0.586 ' O ' HG12 ' A' ' 2' ' ' VAL . 43.8 t -135.48 79.93 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.3 -0.875 . . . . 0.0 109.95 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.501 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -44.22 112.56 0.42 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.375 -0.828 . . . . 0.0 110.639 -179.663 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.574 ' HB2' HG12 ' A' ' 8' ' ' VAL . 1.6 m -73.54 -23.67 60.02 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.793 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.485 ' OD1' ' HB ' ' A' ' 8' ' ' VAL . 12.3 p-10 -160.18 -134.1 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.499 -0.751 . . . . 0.0 109.639 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' MET . . . . . 0.402 ' N ' ' CG ' ' A' ' 5' ' ' ASP . 0.0 OUTLIER -79.71 -42.47 24.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.886 -1.134 . . . . 0.0 110.131 179.81 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 8' ' ' VAL . 3.5 tp10 -121.83 -60.92 1.55 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.21 -0.931 . . . . 0.0 110.012 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.574 HG12 ' HB2' ' A' ' 4' ' ' CYS . 0.9 OUTLIER -42.22 126.4 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 110.072 -179.913 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.501 HD11 ' HB ' ' A' ' 1' ' ' VAL . 9.9 tt -152.22 144.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.307 -0.87 . . . . 0.0 109.949 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.434 ' SG ' ' CB ' ' A' ' 14' ' ' TYR . 0.1 OUTLIER -108.78 160.11 28.51 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.168 -0.958 . . . . 0.0 110.416 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.8 Cg_endo -78.98 42.77 1.34 Allowed 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 124.119 1.589 . . . . 0.0 111.044 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.457 ' OD1' HG23 ' A' ' 2' ' ' VAL . 10.4 m-20 63.04 137.91 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.925 -1.11 . . . . 0.0 110.248 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.67 3.46 56.18 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' TYR . . . . . 0.434 ' CB ' ' SG ' ' A' ' 10' ' ' CYS . 79.2 m-85 -125.06 165.07 18.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.196 -1.179 . . . . 0.0 110.26 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.821 HG22 ' O ' ' A' ' 27' ' ' CYS . 14.7 t -115.49 143.65 45.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.27 -0.894 . . . . 0.0 110.212 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.8 m -78.03 100.47 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.376 -0.828 . . . . 0.0 110.24 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.72 132.84 53.55 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.06 145.73 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.91 . . . . 0.0 110.145 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.88 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -80.86 165.88 42.63 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.306 -0.871 . . . . 0.0 110.115 179.99 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.425 ' HD2' ' HG ' ' A' ' 19' ' ' LEU . 46.5 Cg_endo -73.9 1.39 7.13 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.963 1.507 . . . . 0.0 110.798 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -118.98 32.25 6.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.171 -0.956 . . . . 0.0 110.047 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.94 41.83 95.16 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -120.45 -178.52 3.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.29 -1.124 . . . . 0.0 110.342 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -127.11 149.7 49.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.177 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -161.48 144.56 9.92 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -94.64 132.74 39.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.152 -1.205 . . . . 0.0 110.136 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' CYS . . . . . 0.821 ' O ' HG22 ' A' ' 15' ' ' THR . 13.8 m -121.75 144.99 42.06 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.118 -0.989 . . . . 0.0 110.222 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -73.45 151.48 47.84 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 123.936 1.492 . . . . 0.0 110.175 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.326 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.3 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.285 0.564 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 23.0 t -104.4 56.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 109.733 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.509 ' ND1' ' O ' ' A' ' 3' ' ' HIS . 2.0 p-80 -47.25 128.64 12.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.396 -0.815 . . . . 0.0 110.602 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.8 m -81.93 -34.2 29.98 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.559 179.209 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -146.54 -60.61 0.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.447 -0.783 . . . . 0.0 110.092 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' MET . . . . . 0.53 ' HG3' ' N ' ' A' ' 7' ' ' GLU . 17.1 ptm -176.51 -36.03 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.393 -0.817 . . . . 0.0 109.809 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.53 ' N ' ' HG3' ' A' ' 6' ' ' MET . 6.4 tt0 -107.05 -49.91 3.19 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.384 -0.822 . . . . 0.0 109.891 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.6 t -86.39 104.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.275 -0.891 . . . . 0.0 109.624 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.476 ' C ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -123.89 158.94 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.938 . . . . 0.0 110.216 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -120.21 156.0 55.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.155 -0.966 . . . . 0.0 109.91 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.532 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 44.1 Cg_endo -82.09 32.98 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 123.764 1.402 . . . . 0.0 111.267 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 19.1 t0 66.59 -56.31 0.4 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.101 -0.999 . . . . 0.0 111.183 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.05 -23.71 0.45 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' TYR . . . . . 0.627 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 13.7 m-85 -112.92 173.08 6.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.276 . . . . 0.0 110.913 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 26' ' ' CYS . 4.4 p -106.46 135.19 48.4 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.296 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 25' ' ' GLY . 4.0 t -88.7 104.47 16.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.926 -1.109 . . . . 0.0 111.251 -178.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.1 p -106.76 139.33 41.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.447 -0.783 . . . . 0.0 109.207 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.578 ' HG3' ' CE2' ' A' ' 24' ' ' TRP . 7.1 ttt180 -77.81 137.56 38.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.001 -1.062 . . . . 0.0 110.809 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LEU . . . . . 0.898 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -73.96 177.86 1.9 Allowed Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.51 -0.744 . . . . 0.0 109.968 179.766 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.542 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 45.7 Cg_endo -72.73 -11.12 25.75 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.931 1.49 . . . . 0.0 110.408 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.9 t -108.83 28.47 8.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.181 -0.949 . . . . 0.0 110.133 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.08 12.07 79.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.898 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -85.62 -172.95 4.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.29 -1.123 . . . . 0.0 110.258 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.578 ' CE2' ' HG3' ' A' ' 18' ' ' ARG . 27.7 m95 -137.28 147.19 45.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.342 -0.849 . . . . 0.0 109.875 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 16' ' ' CYS . . . -143.79 151.99 23.81 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.486 ' HA ' ' O ' ' A' ' 15' ' ' THR . 7.5 m -108.58 107.02 17.35 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.298 -1.119 . . . . 0.0 110.08 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.78 132.88 23.01 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.185 -0.947 . . . . 0.0 109.945 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.52 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 44.4 Cg_endo -72.48 149.72 50.53 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 O-C-N 123.68 1.358 . . . . 0.0 110.783 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 3.0 t80 . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.386 -0.821 . . . . 0.0 110.229 -179.977 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.925 HG21 HD11 ' A' ' 9' ' ' ILE . 10.8 m . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.248 0.547 . . . . 0.0 110.275 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' A' ' 4' ' ' CYS . 23.4 t -99.08 82.6 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 110.086 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.511 ' ND1' ' N ' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -51.59 89.77 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 110.476 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.492 ' N ' ' O ' ' A' ' 2' ' ' VAL . 88.8 m -60.14 -19.46 53.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.91 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.451 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 1.8 t0 177.9 -170.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.517 -0.739 . . . . 0.0 109.841 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 12.5 mtt -91.75 14.08 16.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.078 -1.014 . . . . 0.0 110.436 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -127.78 3.02 6.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.886 . . . . 0.0 110.056 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.425 HG13 ' HB2' ' A' ' 4' ' ' CYS . 8.5 p -168.48 154.44 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.37 -0.831 . . . . 0.0 110.098 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.925 HD11 HG21 ' A' ' 1' ' ' VAL . 8.8 tt -146.39 125.52 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.921 . . . . 0.0 110.032 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.461 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 67.3 m -127.95 137.16 30.2 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.18 -0.95 . . . . 0.0 110.219 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.614 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 43.1 Cg_endo -73.06 152.88 51.73 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.838 1.441 . . . . 0.0 110.595 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.457 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 0.6 OUTLIER -37.24 -44.47 0.58 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.719 -0.613 . . . . 0.0 111.487 -179.606 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -62.58 -3.42 5.54 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.7 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' TYR . . . . . 0.614 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 17.9 m-85 -124.26 154.26 40.48 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.445 -1.621 . . . . 0.0 111.52 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.5 p -107.34 137.65 44.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.534 -0.728 . . . . 0.0 109.778 179.639 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.76 142.38 27.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 110.33 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.96 149.21 48.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.302 -0.873 . . . . 0.0 109.983 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.589 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -103.63 129.41 50.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.155 -0.966 . . . . 0.0 110.188 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.974 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -69.78 168.61 16.51 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 110.128 -179.94 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.59 ' HD2' HD23 ' A' ' 19' ' ' LEU . 46.6 Cg_endo -74.7 2.17 6.75 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 124.009 1.531 . . . . 0.0 110.695 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -122.53 33.27 5.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.088 -1.008 . . . . 0.0 110.417 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.53 30.24 73.06 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.974 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -108.27 -174.14 2.45 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.248 -1.148 . . . . 0.0 110.272 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.589 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 31.7 m95 -137.84 147.88 44.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.883 . . . . 0.0 110.276 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.72 156.34 26.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.8 t -118.75 135.57 54.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -1.158 . . . . 0.0 110.527 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.61 125.49 11.99 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.32 164.81 34.23 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 123.787 1.414 . . . . 0.0 110.354 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -119.84 45.01 2.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.91 . . . . 0.0 110.222 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 p -106.76 85.26 2.13 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.252 -0.905 . . . . 0.0 110.222 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.249 179.982 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.597 HG12 ' H ' ' A' ' 2' ' ' VAL . 1.4 t . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.148 0.499 . . . . 0.0 109.692 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.761 HG22 ' O ' ' A' ' 10' ' ' CYS . 24.9 m -112.43 80.25 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.07 -1.019 . . . . 0.0 110.108 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.409 ' C ' ' O ' ' A' ' 2' ' ' VAL . 1.4 m-70 -42.83 125.63 3.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.298 -0.876 . . . . 0.0 110.3 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.414 ' HB3' HG12 ' A' ' 8' ' ' VAL . 0.1 OUTLIER -101.67 -40.0 7.19 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 110.053 179.667 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -145.46 -166.91 2.55 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.862 . . . . 0.0 110.017 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -61.21 -50.19 74.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.155 -0.966 . . . . 0.0 110.244 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.582 ' O ' HG23 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -126.17 61.22 1.28 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 110.293 -179.824 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 7' ' ' GLU . 1.0 OUTLIER -167.19 119.62 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.269 -0.894 . . . . 0.0 109.696 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 10' ' ' CYS . 3.4 mt -131.62 162.32 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.182 -0.949 . . . . 0.0 110.666 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.761 ' O ' HG22 ' A' ' 2' ' ' VAL . 0.1 OUTLIER -136.28 136.31 22.31 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.275 -0.89 . . . . 0.0 109.57 179.523 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.66 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 42.5 Cg_endo -71.27 53.79 1.7 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.753 1.396 . . . . 0.0 111.656 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.509 ' O ' ' N ' ' A' ' 14' ' ' TYR . 19.0 t0 54.12 -77.57 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.59 -0.694 . . . . 0.0 111.808 178.598 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -37.16 -28.93 0.03 OUTLIER Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' TYR . . . . . 0.66 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 24.9 m-85 -92.0 161.88 14.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.118 -1.225 . . . . 0.0 110.657 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.514 HG22 ' O ' ' A' ' 27' ' ' CYS . 0.6 OUTLIER -119.78 145.2 46.8 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.369 -0.832 . . . . 0.0 110.04 179.884 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.22 140.52 36.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -0.851 . . . . 0.0 110.358 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.62 117.14 6.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.256 -0.903 . . . . 0.0 110.119 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -72.06 149.34 44.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.121 -0.987 . . . . 0.0 109.979 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.513 HD23 ' HD2' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -89.36 170.4 10.84 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.188 -0.945 . . . . 0.0 110.566 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.513 ' HD2' HD23 ' A' ' 19' ' ' LEU . 46.3 Cg_endo -73.07 -3.66 14.05 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 124.054 1.555 . . . . 0.0 110.277 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.5 m -109.33 25.64 11.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.299 -0.876 . . . . 0.0 110.038 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.39 51.54 42.28 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.508 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -136.95 -173.2 3.38 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.179 -1.189 . . . . 0.0 110.237 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -120.85 148.31 44.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.226 -0.921 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.74 125.52 1.82 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -96.99 130.24 44.34 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.286 -1.126 . . . . 0.0 109.716 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.514 ' O ' HG22 ' A' ' 15' ' ' THR . 95.6 m -126.88 153.11 76.14 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.149 -0.97 . . . . 0.0 110.568 -179.623 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.93 151.85 51.14 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.12 1.589 . . . . 0.0 110.266 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -121.17 149.12 43.28 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 110.44 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.77 82.09 1.92 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.394 -0.816 . . . . 0.0 110.031 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.6 0 O-C-N 121.297 -0.877 . . . . 0.0 110.268 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.569 HG12 HG23 ' A' ' 2' ' ' VAL . 73.1 t . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.254 0.549 . . . . 0.0 110.2 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.569 HG23 HG12 ' A' ' 1' ' ' VAL . 22.0 t -97.66 72.34 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.145 -0.972 . . . . 0.0 109.86 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.502 ' CE1' HG21 ' A' ' 9' ' ' ILE . 24.8 m-70 -46.05 106.67 0.08 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.339 -0.851 . . . . 0.0 110.668 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.497 ' HB3' ' O ' ' A' ' 8' ' ' VAL . 7.1 t -89.01 -25.64 21.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.259 -0.901 . . . . 0.0 109.632 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -156.87 -139.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.386 -0.821 . . . . 0.0 109.764 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 55.1 mtm -79.82 -50.5 10.44 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.1 -1.0 . . . . 0.0 110.023 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -122.89 -1.31 8.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.29 -0.881 . . . . 0.0 110.22 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.497 ' O ' ' HB3' ' A' ' 4' ' ' CYS . 45.0 t -89.97 75.77 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.187 -0.946 . . . . 0.0 110.252 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.502 HG21 ' CE1' ' A' ' 3' ' ' HIS . 6.8 pt -112.07 126.82 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.058 -1.026 . . . . 0.0 109.997 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -109.95 157.92 36.44 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.28 -0.887 . . . . 0.0 110.172 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.473 ' O ' ' N ' ' A' ' 13' ' ' GLY . 48.2 Cg_endo -81.15 41.06 1.08 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.873 1.46 . . . . 0.0 110.944 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.54 ' OD1' HG21 ' A' ' 2' ' ' VAL . 0.3 OUTLIER 66.34 -57.97 0.36 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.051 -1.031 . . . . 0.0 110.817 179.528 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.473 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.0 -25.02 0.59 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' TYR . . . . . 0.469 ' CD1' ' HD2' ' A' ' 11' ' ' PRO . 54.3 m-85 -96.04 163.66 13.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.035 -1.274 . . . . 0.0 110.826 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.749 HG22 ' O ' ' A' ' 27' ' ' CYS . 0.7 OUTLIER -113.62 131.14 56.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.473 -0.767 . . . . 0.0 109.459 179.018 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.4 t -90.54 102.38 15.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.518 -0.739 . . . . 0.0 110.373 -179.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -112.25 137.57 50.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.836 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.2 mtm105 -92.11 131.86 37.05 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 110.055 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.587 HD23 ' HD2' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -67.67 165.76 27.96 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.335 -0.853 . . . . 0.0 110.138 179.977 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.587 ' HD2' HD23 ' A' ' 19' ' ' LEU . 43.9 Cg_endo -69.62 -5.29 15.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.962 1.507 . . . . 0.0 110.325 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.15 26.99 7.03 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.413 -0.804 . . . . 0.0 110.113 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.83 27.23 72.55 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -109.38 171.0 7.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.13 -1.218 . . . . 0.0 110.389 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.1 m95 -111.2 150.51 29.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.304 -0.872 . . . . 0.0 109.864 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.76 109.27 0.41 Allowed Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.086 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -93.52 115.94 28.46 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.214 -1.168 . . . . 0.0 109.65 179.222 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.749 ' O ' HG22 ' A' ' 15' ' ' THR . 25.0 p -129.93 153.2 80.93 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.135 -0.978 . . . . 0.0 110.586 -179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.82 149.84 48.64 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.045 1.55 . . . . 0.0 110.244 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 29' ' ' PHE . 72.4 t80 -147.63 59.84 1.14 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.23 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.755 ' O ' HG23 ' A' ' 30' ' ' THR . 15.3 t -116.18 69.92 0.75 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 110.254 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? . . . . . 0 N--CA 1.492 1.652 0 O-C-N 121.18 -0.95 . . . . 0.0 110.116 179.904 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.421 HG13 ' H3 ' ' A' ' 1' ' ' VAL . 28.4 m . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.236 0.541 . . . . 0.0 110.327 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.507 ' HB ' ' O ' ' A' ' 10' ' ' CYS . 21.0 t -108.04 100.82 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.916 . . . . 0.0 110.117 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -81.53 89.84 6.21 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.197 -0.939 . . . . 0.0 110.105 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 44.9 m -84.74 4.45 32.69 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.21 -0.931 . . . . 0.0 110.381 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -168.88 -166.45 0.65 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.19 -0.944 . . . . 0.0 110.359 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 24.2 mtm -97.07 -27.15 14.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 110.603 -179.688 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -108.41 -47.83 3.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.098 -1.001 . . . . 0.0 110.769 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.484 ' C ' ' CG2' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -90.09 137.93 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.097 -1.002 . . . . 0.0 110.27 -179.821 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.484 ' CG2' ' C ' ' A' ' 8' ' ' VAL . 4.4 pt -151.2 131.19 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.258 -0.901 . . . . 0.0 110.092 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.507 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 20.5 m -122.71 162.68 37.25 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.957 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -82.93 173.34 10.27 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.736 1.388 . . . . 0.0 110.564 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -63.79 -19.22 64.83 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.288 -0.883 . . . . 0.0 111.217 -179.107 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.14 -4.91 38.39 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -132.24 175.16 9.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.032 -1.275 . . . . 0.0 110.956 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.0 p -128.56 119.01 24.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.626 -0.671 . . . . 0.0 109.331 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.419 ' O ' ' SG ' ' A' ' 16' ' ' CYS . 28.9 p -82.15 123.47 29.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.241 -0.912 . . . . 0.0 110.654 -179.287 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 m -118.05 127.4 53.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.506 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -82.37 122.68 28.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.186 -0.946 . . . . 0.0 110.331 -179.787 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 1.019 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -67.66 170.37 7.2 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.175 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.523 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 47.9 Cg_endo -72.98 -20.02 22.5 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 O-C-N 124.049 1.552 . . . . 0.0 110.661 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.8 m -99.14 31.66 2.97 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.17 -0.956 . . . . 0.0 110.074 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.62 41.54 93.93 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 1.019 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -114.94 -172.74 2.18 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.174 -1.192 . . . . 0.0 110.336 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.506 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 20.3 m95 -140.04 147.95 41.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.927 . . . . 0.0 110.236 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 113.84 0.81 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.67 106.47 18.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -1.162 . . . . 0.0 109.993 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.8 m -119.21 139.39 27.46 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 110.232 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.47 148.22 47.86 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.017 1.535 . . . . 0.0 110.646 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 4.7 t80 -72.57 110.95 7.31 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.404 -0.81 . . . . 0.0 109.872 179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.6 t -134.27 63.07 1.63 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.285 -0.884 . . . . 0.0 110.159 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.4 mp0 . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.218 -0.926 . . . . 0.0 110.269 -179.931 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.869 ' CG2' HD11 ' A' ' 9' ' ' ILE . 5.5 m . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.288 0.566 . . . . 0.0 110.309 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.831 HG12 ' O ' ' A' ' 10' ' ' CYS . 3.1 p -122.32 88.88 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.34 -0.85 . . . . 0.0 110.059 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.508 ' ND1' ' O ' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -59.07 82.32 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 110.429 -179.71 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.479 ' N ' ' O ' ' A' ' 2' ' ' VAL . 0.4 OUTLIER -54.13 -28.46 39.88 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.189 -0.944 . . . . 0.0 109.817 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.91 -163.79 1.86 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.356 -0.84 . . . . 0.0 109.892 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -98.96 15.57 25.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.077 -1.014 . . . . 0.0 110.601 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.492 ' HG3' ' N ' ' A' ' 8' ' ' VAL . 11.1 pt-20 -136.61 -33.16 0.8 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.102 -0.999 . . . . 0.0 110.651 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.492 ' N ' ' HG3' ' A' ' 7' ' ' GLU . 9.4 p -116.49 162.44 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.085 -1.009 . . . . 0.0 110.401 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.869 HD11 ' CG2' ' A' ' 1' ' ' VAL . 3.5 tt -157.55 133.97 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.292 -0.88 . . . . 0.0 110.323 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.831 ' O ' HG12 ' A' ' 2' ' ' VAL . 51.2 m -107.73 144.18 28.78 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.082 -1.011 . . . . 0.0 109.589 179.489 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 13' ' ' GLY . 46.7 Cg_endo -80.33 38.01 0.72 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.675 1.355 . . . . 0.0 111.267 -179.738 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 3.0 t0 66.32 -56.33 0.38 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 110.859 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.22 -31.78 0.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' TYR . . . . . 0.515 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 47.5 m-85 -103.36 173.14 6.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.196 -1.179 . . . . 0.0 110.309 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.595 HG23 ' CD1' ' A' ' 29' ' ' PHE . 37.5 p -115.54 125.88 53.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.423 -0.798 . . . . 0.0 109.969 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 8.1 t -49.09 126.37 12.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 110.22 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.3 m -146.55 142.07 27.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 110.153 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.611 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -97.03 141.98 29.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 110.401 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.755 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -76.3 160.32 78.07 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 0.0 110.181 179.904 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.52 -6.97 20.06 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.985 1.518 . . . . 0.0 110.653 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 t -107.41 29.58 7.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 110.307 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.05 67.45 1.96 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.755 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -155.13 174.43 15.2 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -1.107 . . . . 0.0 110.148 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.611 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 14.6 m95 -123.06 147.63 46.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.237 -0.914 . . . . 0.0 110.252 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -165.94 155.24 26.38 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.496 ' HB3' ' HB2' ' A' ' 14' ' ' TYR . 7.8 m -98.33 125.75 43.58 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.223 -1.163 . . . . 0.0 109.862 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 1.1 m -109.61 129.45 23.91 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.156 -0.965 . . . . 0.0 110.397 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.78 155.15 54.03 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.782 1.411 . . . . 0.0 109.9 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.806 ' CE2' HG22 ' A' ' 30' ' ' THR . 4.6 p90 -147.66 -45.42 0.17 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.124 -0.985 . . . . 0.0 110.859 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.806 HG22 ' CE2' ' A' ' 29' ' ' PHE . 3.7 t -139.57 52.83 1.71 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.932 -1.105 . . . . 0.0 110.625 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 18.7 mt-30 . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.036 -1.04 . . . . 0.0 110.205 179.807 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.545 ' HB ' ' CD1' ' A' ' 9' ' ' ILE . 6.9 m . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.31 0.576 . . . . 0.0 110.22 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.55 HG21 ' OD2' ' A' ' 12' ' ' ASP . 44.6 t -105.5 103.72 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 110.292 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.405 ' C ' ' O ' ' A' ' 2' ' ' VAL . 14.2 m-70 -44.02 118.75 1.55 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.186 -0.946 . . . . 0.0 110.493 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -79.93 -37.77 33.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.322 -0.861 . . . . 0.0 109.693 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -169.54 -80.08 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.451 -0.781 . . . . 0.0 110.276 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 9.4 tpp -146.15 -53.79 0.26 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.136 -0.977 . . . . 0.0 110.59 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -102.84 13.14 35.11 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.104 -0.997 . . . . 0.0 110.205 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -138.17 141.08 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.345 -0.847 . . . . 0.0 110.08 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.545 ' CD1' ' HB ' ' A' ' 1' ' ' VAL . 0.0 OUTLIER -145.15 127.96 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 110.004 -179.825 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.465 ' SG ' ' HB2' ' A' ' 14' ' ' TYR . 0.5 OUTLIER -118.65 154.85 52.74 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.053 -1.03 . . . . 0.0 110.297 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.478 ' O ' ' N ' ' A' ' 13' ' ' GLY . 48.0 Cg_endo -78.59 43.14 1.38 Allowed 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.964 1.508 . . . . 0.0 111.434 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.55 ' OD2' HG21 ' A' ' 2' ' ' VAL . 3.8 t70 65.05 -58.95 0.26 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 111.137 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.41 -26.48 0.22 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 28' ' ' PRO . 92.1 m-85 -100.87 153.43 19.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.952 -1.322 . . . . 0.0 110.955 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . 1.081 HG22 ' O ' ' A' ' 27' ' ' CYS . 10.1 t -102.43 146.18 28.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 109.784 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -94.74 122.11 37.01 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.34 -0.85 . . . . 0.0 110.684 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -139.77 144.1 37.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.38 -0.825 . . . . 0.0 109.571 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.594 ' HG3' ' CH2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -92.34 134.76 34.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.511 -179.581 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.504 ' CG ' ' HD2' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -64.59 171.93 2.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.386 -0.821 . . . . 0.0 110.431 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.504 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 49.9 Cg_endo -76.2 1.55 8.17 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.062 1.559 . . . . 0.0 110.713 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 69.0 m -117.69 29.56 7.77 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.211 -0.93 . . . . 0.0 110.483 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.49 58.58 9.09 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.51 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . -145.56 168.29 20.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.299 -1.118 . . . . 0.0 109.857 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.594 ' CH2' ' HG3' ' A' ' 18' ' ' ARG . 2.0 m95 -105.14 147.6 27.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.126 -0.984 . . . . 0.0 110.203 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -154.02 133.63 4.0 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.19 128.31 48.75 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -1.157 . . . . 0.0 110.008 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 1.081 ' O ' HG22 ' A' ' 15' ' ' THR . 76.7 m -124.38 133.15 24.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 110.379 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.479 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 50.1 Cg_endo -75.48 149.8 35.28 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.867 1.456 . . . . 0.0 110.249 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.57 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 11.7 p90 -134.39 140.9 46.63 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.213 -0.93 . . . . 0.0 110.321 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 15.9 m -89.29 157.15 18.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.885 . . . . 0.0 110.097 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.211 -0.931 . . . . 0.0 110.18 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 121.348 0.594 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 89.3 t -105.96 -25.34 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.94 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 56.07 93.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.333 -0.854 . . . . 0.0 110.348 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.3 m -61.93 -36.95 82.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.915 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -163.4 -153.61 0.25 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.298 -0.876 . . . . 0.0 110.332 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -80.82 -15.74 55.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.227 -0.92 . . . . 0.0 110.619 -179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -135.35 23.23 3.46 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.222 -0.924 . . . . 0.0 110.514 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 16.6 t -142.98 149.29 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.09 -1.006 . . . . 0.0 110.254 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 6.2 tt -163.04 143.22 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.228 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.449 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -119.94 168.98 9.18 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.864 . . . . 0.0 110.145 -179.918 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.3 Cg_endo -80.25 38.84 0.78 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 124.092 1.575 . . . . 0.0 111.198 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.456 ' HB2' ' O ' ' A' ' 11' ' ' PRO . 1.4 m-20 66.69 138.19 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 120.948 -1.095 . . . . 0.0 110.377 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.48 42.88 7.64 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' TYR . . . . . 0.421 ' CD1' ' HA ' ' A' ' 28' ' ' PRO . 22.0 m-85 -150.59 151.91 33.29 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.201 -1.176 . . . . 0.0 110.543 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.755 HG22 ' O ' ' A' ' 27' ' ' CYS . 5.7 t -104.98 146.68 28.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.803 . . . . 0.0 110.109 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.7 m -97.83 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.305 -0.872 . . . . 0.0 110.226 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.8 m -111.0 127.15 55.43 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.194 -0.941 . . . . 0.0 110.152 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.581 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -85.69 124.79 32.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.121 -0.987 . . . . 0.0 110.435 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.808 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -72.0 161.73 77.24 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.29 -0.881 . . . . 0.0 110.054 179.924 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -74.16 -5.83 17.56 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.951 1.501 . . . . 0.0 110.548 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 t -111.56 31.81 5.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.27 -0.894 . . . . 0.0 110.246 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.67 68.75 1.55 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.808 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -155.58 179.6 9.03 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.317 -1.108 . . . . 0.0 110.182 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 24.8 m95 -134.57 147.27 50.23 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -0.865 . . . . 0.0 110.18 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.8 133.31 6.31 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -97.25 112.56 24.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -1.166 . . . . 0.0 110.29 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.755 ' O ' HG22 ' A' ' 15' ' ' THR . 1.3 m -105.56 144.43 28.83 Favored Pre-proline 0 N--CA 1.493 1.675 0 O-C-N 121.309 -0.869 . . . . 0.0 110.067 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' CD1' ' A' ' 14' ' ' TYR . 44.0 Cg_endo -70.92 149.08 58.92 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.805 1.424 . . . . 0.0 110.717 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -153.6 20.56 0.54 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 110.328 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 34.6 p -103.88 31.17 4.64 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.186 -0.946 . . . . 0.0 110.409 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.9 pt20 . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.169 -0.957 . . . . 0.0 110.182 -179.995 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.403 HG23 HD11 ' A' ' 9' ' ' ILE . 20.0 m . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.202 0.525 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 85.4 t -107.69 146.78 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.298 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.434 ' O ' ' C ' ' A' ' 4' ' ' CYS . 10.9 t60 -70.56 80.78 0.58 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.2 -0.938 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.49 ' HB3' ' HB ' ' A' ' 8' ' ' VAL . 3.7 t -40.8 -52.98 2.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.395 -0.816 . . . . 0.0 110.536 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 1.2 t0 -145.46 -147.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.125 -0.985 . . . . 0.0 110.288 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -78.04 -33.81 50.82 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.227 -0.92 . . . . 0.0 110.444 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -126.93 20.47 7.0 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.107 -0.996 . . . . 0.0 110.471 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.49 ' HB ' ' HB3' ' A' ' 4' ' ' CYS . 16.3 t -126.8 152.52 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.282 -0.886 . . . . 0.0 109.931 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 9' ' ' ILE . 0.7 OUTLIER -146.04 105.82 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.095 -1.003 . . . . 0.0 110.825 -179.619 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 84.1 m -121.07 161.19 41.82 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.267 -0.895 . . . . 0.0 109.546 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.599 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 40.5 Cg_endo -72.71 154.99 54.49 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.787 1.414 . . . . 0.0 110.881 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -48.86 -19.16 0.35 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.564 -0.71 . . . . 0.0 111.544 -178.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.431 ' O ' ' CD1' ' A' ' 14' ' ' TYR . . . -87.24 32.27 4.17 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' TYR . . . . . 0.599 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 11.6 m-85 -140.78 162.35 35.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.064 -1.257 . . . . 0.0 110.833 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.924 HG22 ' O ' ' A' ' 27' ' ' CYS . 1.0 OUTLIER -128.99 118.27 22.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.519 -0.738 . . . . 0.0 109.419 179.482 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 130.44 40.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.375 -0.828 . . . . 0.0 110.863 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -144.02 131.17 20.65 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.704 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.41 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -81.4 132.26 35.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 110.21 -179.817 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.903 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -62.98 165.35 10.37 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.337 -0.852 . . . . 0.0 110.093 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.489 ' HD2' HD23 ' A' ' 19' ' ' LEU . 50.0 Cg_endo -80.01 41.58 1.15 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.955 1.503 . . . . 0.0 110.848 179.76 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -168.33 30.05 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.029 -1.044 . . . . 0.0 110.488 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.78 61.47 3.09 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.903 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -151.41 170.68 18.98 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.314 -1.109 . . . . 0.0 110.097 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.421 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 1.7 m95 -116.19 149.22 39.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.139 -0.975 . . . . 0.0 110.466 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.76 123.57 1.03 Allowed Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 15' ' ' THR . 26.3 p -97.28 130.09 44.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 110.235 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.924 ' O ' HG22 ' A' ' 15' ' ' THR . 0.0 OUTLIER -100.0 150.07 36.55 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.26 -0.9 . . . . 0.0 109.906 179.851 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.97 145.89 63.25 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.797 1.42 . . . . 0.0 110.58 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -87.83 119.81 28.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.528 -0.733 . . . . 0.0 109.982 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.2 t -143.26 37.65 1.39 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.296 -0.878 . . . . 0.0 110.169 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.262 -0.899 . . . . 0.0 110.062 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.501 ' HB ' HD11 ' A' ' 9' ' ' ILE . 17.1 m . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.16 0.505 . . . . 0.0 110.236 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.586 ' O ' HG12 ' A' ' 2' ' ' VAL . 43.8 t -135.48 79.93 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.3 -0.875 . . . . 0.0 109.95 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.501 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -44.22 112.56 0.42 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.375 -0.828 . . . . 0.0 110.639 -179.663 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.574 ' HB2' HG12 ' A' ' 8' ' ' VAL . 1.6 m -73.54 -23.67 60.02 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.793 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.485 ' OD1' ' HB ' ' A' ' 8' ' ' VAL . 12.3 p-10 -160.18 -134.1 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.499 -0.751 . . . . 0.0 109.639 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' MET . . . . . 0.402 ' N ' ' CG ' ' A' ' 5' ' ' ASP . 0.0 OUTLIER -79.71 -42.47 24.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.886 -1.134 . . . . 0.0 110.131 179.81 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 8' ' ' VAL . 3.5 tp10 -121.83 -60.92 1.55 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.21 -0.931 . . . . 0.0 110.012 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.574 HG12 ' HB2' ' A' ' 4' ' ' CYS . 0.9 OUTLIER -42.22 126.4 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 110.072 -179.913 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.501 HD11 ' HB ' ' A' ' 1' ' ' VAL . 9.9 tt -152.22 144.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.307 -0.87 . . . . 0.0 109.949 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.434 ' SG ' ' CB ' ' A' ' 14' ' ' TYR . 0.1 OUTLIER -108.78 160.11 28.51 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.168 -0.958 . . . . 0.0 110.416 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.8 Cg_endo -78.98 42.77 1.34 Allowed 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 124.119 1.589 . . . . 0.0 111.044 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.457 ' OD1' HG23 ' A' ' 2' ' ' VAL . 10.4 m-20 63.04 137.91 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.925 -1.11 . . . . 0.0 110.248 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.67 3.46 56.18 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' TYR . . . . . 0.434 ' CB ' ' SG ' ' A' ' 10' ' ' CYS . 79.2 m-85 -125.06 165.07 18.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.196 -1.179 . . . . 0.0 110.26 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.821 HG22 ' O ' ' A' ' 27' ' ' CYS . 14.7 t -115.49 143.65 45.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.27 -0.894 . . . . 0.0 110.212 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.8 m -78.03 100.47 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.376 -0.828 . . . . 0.0 110.24 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.72 132.84 53.55 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.06 145.73 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.91 . . . . 0.0 110.145 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.88 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -80.86 165.88 42.63 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.306 -0.871 . . . . 0.0 110.115 179.99 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.425 ' HD2' ' HG ' ' A' ' 19' ' ' LEU . 46.5 Cg_endo -73.9 1.39 7.13 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.963 1.507 . . . . 0.0 110.798 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -118.98 32.25 6.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.171 -0.956 . . . . 0.0 110.047 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.94 41.83 95.16 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -120.45 -178.52 3.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.29 -1.124 . . . . 0.0 110.342 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -127.11 149.7 49.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.177 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -161.48 144.56 9.92 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -94.64 132.74 39.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.152 -1.205 . . . . 0.0 110.136 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' CYS . . . . . 0.821 ' O ' HG22 ' A' ' 15' ' ' THR . 13.8 m -121.75 144.99 42.06 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.118 -0.989 . . . . 0.0 110.222 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -73.45 151.48 47.84 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 123.936 1.492 . . . . 0.0 110.175 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -158.53 53.74 0.43 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.326 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.0 t -114.14 31.4 6.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.37 -0.831 . . . . 0.0 109.95 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 10.4 mm-40 . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.916 . . . . 0.0 110.225 -179.935 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.3 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.285 0.564 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 23.0 t -104.4 56.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 109.733 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.509 ' ND1' ' O ' ' A' ' 3' ' ' HIS . 2.0 p-80 -47.25 128.64 12.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.396 -0.815 . . . . 0.0 110.602 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.8 m -81.93 -34.2 29.98 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.559 179.209 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -146.54 -60.61 0.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.447 -0.783 . . . . 0.0 110.092 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' MET . . . . . 0.53 ' HG3' ' N ' ' A' ' 7' ' ' GLU . 17.1 ptm -176.51 -36.03 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.393 -0.817 . . . . 0.0 109.809 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.53 ' N ' ' HG3' ' A' ' 6' ' ' MET . 6.4 tt0 -107.05 -49.91 3.19 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.384 -0.822 . . . . 0.0 109.891 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.6 t -86.39 104.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.275 -0.891 . . . . 0.0 109.624 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.476 ' C ' HD13 ' A' ' 9' ' ' ILE . 0.0 OUTLIER -123.89 158.94 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.938 . . . . 0.0 110.216 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -120.21 156.0 55.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.155 -0.966 . . . . 0.0 109.91 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.532 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 44.1 Cg_endo -82.09 32.98 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 123.764 1.402 . . . . 0.0 111.267 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 19.1 t0 66.59 -56.31 0.4 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.101 -0.999 . . . . 0.0 111.183 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.05 -23.71 0.45 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' TYR . . . . . 0.627 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 13.7 m-85 -112.92 173.08 6.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.276 . . . . 0.0 110.913 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 26' ' ' CYS . 4.4 p -106.46 135.19 48.4 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.296 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 25' ' ' GLY . 4.0 t -88.7 104.47 16.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.926 -1.109 . . . . 0.0 111.251 -178.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.1 p -106.76 139.33 41.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.447 -0.783 . . . . 0.0 109.207 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.578 ' HG3' ' CE2' ' A' ' 24' ' ' TRP . 7.1 ttt180 -77.81 137.56 38.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.001 -1.062 . . . . 0.0 110.809 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . 0.898 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -73.96 177.86 1.9 Allowed Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.51 -0.744 . . . . 0.0 109.968 179.766 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.542 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 45.7 Cg_endo -72.73 -11.12 25.75 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.931 1.49 . . . . 0.0 110.408 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.9 t -108.83 28.47 8.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.181 -0.949 . . . . 0.0 110.133 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.08 12.07 79.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.898 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -85.62 -172.95 4.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.29 -1.123 . . . . 0.0 110.258 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.578 ' CE2' ' HG3' ' A' ' 18' ' ' ARG . 27.7 m95 -137.28 147.19 45.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.342 -0.849 . . . . 0.0 109.875 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 16' ' ' CYS . . . -143.79 151.99 23.81 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.486 ' HA ' ' O ' ' A' ' 15' ' ' THR . 7.5 m -108.58 107.02 17.35 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.298 -1.119 . . . . 0.0 110.08 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.78 132.88 23.01 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.185 -0.947 . . . . 0.0 109.945 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.52 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 44.4 Cg_endo -72.48 149.72 50.53 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 O-C-N 123.68 1.358 . . . . 0.0 110.783 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -117.1 99.41 7.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.386 -0.821 . . . . 0.0 110.229 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.66 ' O ' HG23 ' A' ' 30' ' ' THR . 6.1 t -144.41 101.17 3.65 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.282 -0.886 . . . . 0.0 110.013 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 9.6 mm100 . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.276 -0.89 . . . . 0.0 110.189 -179.799 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.925 HG21 HD11 ' A' ' 9' ' ' ILE . 10.8 m . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.248 0.547 . . . . 0.0 110.275 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' A' ' 4' ' ' CYS . 23.4 t -99.08 82.6 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 110.086 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.511 ' ND1' ' N ' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -51.59 89.77 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 110.476 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.492 ' N ' ' O ' ' A' ' 2' ' ' VAL . 88.8 m -60.14 -19.46 53.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.91 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.451 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 1.8 t0 177.9 -170.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.517 -0.739 . . . . 0.0 109.841 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 12.5 mtt -91.75 14.08 16.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.078 -1.014 . . . . 0.0 110.436 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -127.78 3.02 6.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.886 . . . . 0.0 110.056 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.425 HG13 ' HB2' ' A' ' 4' ' ' CYS . 8.5 p -168.48 154.44 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.37 -0.831 . . . . 0.0 110.098 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.925 HD11 HG21 ' A' ' 1' ' ' VAL . 8.8 tt -146.39 125.52 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.921 . . . . 0.0 110.032 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.461 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 67.3 m -127.95 137.16 30.2 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.18 -0.95 . . . . 0.0 110.219 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.614 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 43.1 Cg_endo -73.06 152.88 51.73 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.838 1.441 . . . . 0.0 110.595 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.457 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 0.6 OUTLIER -37.24 -44.47 0.58 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.719 -0.613 . . . . 0.0 111.487 -179.606 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -62.58 -3.42 5.54 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.7 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . 0.614 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 17.9 m-85 -124.26 154.26 40.48 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.445 -1.621 . . . . 0.0 111.52 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.5 p -107.34 137.65 44.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.534 -0.728 . . . . 0.0 109.778 179.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.76 142.38 27.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 110.33 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.96 149.21 48.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.302 -0.873 . . . . 0.0 109.983 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.589 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -103.63 129.41 50.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.155 -0.966 . . . . 0.0 110.188 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.974 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -69.78 168.61 16.51 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 110.128 -179.94 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.59 ' HD2' HD23 ' A' ' 19' ' ' LEU . 46.6 Cg_endo -74.7 2.17 6.75 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 124.009 1.531 . . . . 0.0 110.695 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -122.53 33.27 5.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.088 -1.008 . . . . 0.0 110.417 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.53 30.24 73.06 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.974 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -108.27 -174.14 2.45 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.248 -1.148 . . . . 0.0 110.272 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.589 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 31.7 m95 -137.84 147.88 44.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.883 . . . . 0.0 110.276 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.72 156.34 26.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.8 t -118.75 135.57 54.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -1.158 . . . . 0.0 110.527 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.61 125.49 11.99 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.32 164.81 34.23 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 123.787 1.414 . . . . 0.0 110.354 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.91 . . . . 0.0 110.222 -179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.597 HG12 ' H ' ' A' ' 2' ' ' VAL . 1.4 t . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.148 0.499 . . . . 0.0 109.692 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.761 HG22 ' O ' ' A' ' 10' ' ' CYS . 24.9 m -112.43 80.25 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.07 -1.019 . . . . 0.0 110.108 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.409 ' C ' ' O ' ' A' ' 2' ' ' VAL . 1.4 m-70 -42.83 125.63 3.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.298 -0.876 . . . . 0.0 110.3 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.414 ' HB3' HG12 ' A' ' 8' ' ' VAL . 0.1 OUTLIER -101.67 -40.0 7.19 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 110.053 179.667 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -145.46 -166.91 2.55 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.862 . . . . 0.0 110.017 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -61.21 -50.19 74.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.155 -0.966 . . . . 0.0 110.244 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.582 ' O ' HG23 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -126.17 61.22 1.28 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 110.293 -179.824 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 7' ' ' GLU . 1.0 OUTLIER -167.19 119.62 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.269 -0.894 . . . . 0.0 109.696 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 10' ' ' CYS . 3.4 mt -131.62 162.32 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.182 -0.949 . . . . 0.0 110.666 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.761 ' O ' HG22 ' A' ' 2' ' ' VAL . 0.1 OUTLIER -136.28 136.31 22.31 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.275 -0.89 . . . . 0.0 109.57 179.523 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.66 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 42.5 Cg_endo -71.27 53.79 1.7 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.753 1.396 . . . . 0.0 111.656 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.509 ' O ' ' N ' ' A' ' 14' ' ' TYR . 19.0 t0 54.12 -77.57 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.59 -0.694 . . . . 0.0 111.808 178.598 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -37.16 -28.93 0.03 OUTLIER Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . 0.66 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 24.9 m-85 -92.0 161.88 14.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.118 -1.225 . . . . 0.0 110.657 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.514 HG22 ' O ' ' A' ' 27' ' ' CYS . 0.6 OUTLIER -119.78 145.2 46.8 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.369 -0.832 . . . . 0.0 110.04 179.884 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.22 140.52 36.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -0.851 . . . . 0.0 110.358 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.62 117.14 6.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.256 -0.903 . . . . 0.0 110.119 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -72.06 149.34 44.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.121 -0.987 . . . . 0.0 109.979 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.513 HD23 ' HD2' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -89.36 170.4 10.84 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.188 -0.945 . . . . 0.0 110.566 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.513 ' HD2' HD23 ' A' ' 19' ' ' LEU . 46.3 Cg_endo -73.07 -3.66 14.05 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 124.054 1.555 . . . . 0.0 110.277 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.5 m -109.33 25.64 11.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.299 -0.876 . . . . 0.0 110.038 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.39 51.54 42.28 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.508 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -136.95 -173.2 3.38 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.179 -1.189 . . . . 0.0 110.237 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -120.85 148.31 44.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.226 -0.921 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.74 125.52 1.82 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -96.99 130.24 44.34 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.286 -1.126 . . . . 0.0 109.716 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.514 ' O ' HG22 ' A' ' 15' ' ' THR . 95.6 m -126.88 153.11 76.14 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.149 -0.97 . . . . 0.0 110.568 -179.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.93 151.85 51.14 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.12 1.589 . . . . 0.0 110.266 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 110.44 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.569 HG12 HG23 ' A' ' 2' ' ' VAL . 73.1 t . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.254 0.549 . . . . 0.0 110.2 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.569 HG23 HG12 ' A' ' 1' ' ' VAL . 22.0 t -97.66 72.34 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.145 -0.972 . . . . 0.0 109.86 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.502 ' CE1' HG21 ' A' ' 9' ' ' ILE . 24.8 m-70 -46.05 106.67 0.08 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.339 -0.851 . . . . 0.0 110.668 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.497 ' HB3' ' O ' ' A' ' 8' ' ' VAL . 7.1 t -89.01 -25.64 21.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.259 -0.901 . . . . 0.0 109.632 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -156.87 -139.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.386 -0.821 . . . . 0.0 109.764 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 55.1 mtm -79.82 -50.5 10.44 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.1 -1.0 . . . . 0.0 110.023 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -122.89 -1.31 8.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.29 -0.881 . . . . 0.0 110.22 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.497 ' O ' ' HB3' ' A' ' 4' ' ' CYS . 45.0 t -89.97 75.77 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.187 -0.946 . . . . 0.0 110.252 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.502 HG21 ' CE1' ' A' ' 3' ' ' HIS . 6.8 pt -112.07 126.82 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.058 -1.026 . . . . 0.0 109.997 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -109.95 157.92 36.44 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.28 -0.887 . . . . 0.0 110.172 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.473 ' O ' ' N ' ' A' ' 13' ' ' GLY . 48.2 Cg_endo -81.15 41.06 1.08 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.873 1.46 . . . . 0.0 110.944 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.54 ' OD1' HG21 ' A' ' 2' ' ' VAL . 0.3 OUTLIER 66.34 -57.97 0.36 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.051 -1.031 . . . . 0.0 110.817 179.528 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.473 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.0 -25.02 0.59 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . 0.469 ' CD1' ' HD2' ' A' ' 11' ' ' PRO . 54.3 m-85 -96.04 163.66 13.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.035 -1.274 . . . . 0.0 110.826 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.749 HG22 ' O ' ' A' ' 27' ' ' CYS . 0.7 OUTLIER -113.62 131.14 56.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.473 -0.767 . . . . 0.0 109.459 179.018 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.4 t -90.54 102.38 15.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.518 -0.739 . . . . 0.0 110.373 -179.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -112.25 137.57 50.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.836 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.2 mtm105 -92.11 131.86 37.05 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 110.055 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.587 HD23 ' HD2' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -67.67 165.76 27.96 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.335 -0.853 . . . . 0.0 110.138 179.977 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.587 ' HD2' HD23 ' A' ' 19' ' ' LEU . 43.9 Cg_endo -69.62 -5.29 15.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.962 1.507 . . . . 0.0 110.325 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.15 26.99 7.03 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.413 -0.804 . . . . 0.0 110.113 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.83 27.23 72.55 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -109.38 171.0 7.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.13 -1.218 . . . . 0.0 110.389 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.1 m95 -111.2 150.51 29.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.304 -0.872 . . . . 0.0 109.864 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.76 109.27 0.41 Allowed Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.086 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -93.52 115.94 28.46 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.214 -1.168 . . . . 0.0 109.65 179.222 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.749 ' O ' HG22 ' A' ' 15' ' ' THR . 25.0 p -129.93 153.2 80.93 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.135 -0.978 . . . . 0.0 110.586 -179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.82 149.84 48.64 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.045 1.55 . . . . 0.0 110.244 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 29' ' ' PHE . 72.4 t80 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.23 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.421 HG13 ' H3 ' ' A' ' 1' ' ' VAL . 28.4 m . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.236 0.541 . . . . 0.0 110.327 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.507 ' HB ' ' O ' ' A' ' 10' ' ' CYS . 21.0 t -108.04 100.82 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.916 . . . . 0.0 110.117 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -81.53 89.84 6.21 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.197 -0.939 . . . . 0.0 110.105 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 44.9 m -84.74 4.45 32.69 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.21 -0.931 . . . . 0.0 110.381 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -168.88 -166.45 0.65 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.19 -0.944 . . . . 0.0 110.359 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 24.2 mtm -97.07 -27.15 14.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 110.603 -179.688 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -108.41 -47.83 3.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.098 -1.001 . . . . 0.0 110.769 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.484 ' C ' ' CG2' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -90.09 137.93 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.097 -1.002 . . . . 0.0 110.27 -179.821 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.484 ' CG2' ' C ' ' A' ' 8' ' ' VAL . 4.4 pt -151.2 131.19 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.258 -0.901 . . . . 0.0 110.092 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.507 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 20.5 m -122.71 162.68 37.25 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.957 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -82.93 173.34 10.27 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.736 1.388 . . . . 0.0 110.564 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -63.79 -19.22 64.83 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.288 -0.883 . . . . 0.0 111.217 -179.107 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.14 -4.91 38.39 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -132.24 175.16 9.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.032 -1.275 . . . . 0.0 110.956 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.0 p -128.56 119.01 24.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.626 -0.671 . . . . 0.0 109.331 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.419 ' O ' ' SG ' ' A' ' 16' ' ' CYS . 28.9 p -82.15 123.47 29.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.241 -0.912 . . . . 0.0 110.654 -179.287 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 m -118.05 127.4 53.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.506 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -82.37 122.68 28.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.186 -0.946 . . . . 0.0 110.331 -179.787 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 1.019 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -67.66 170.37 7.2 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.175 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.523 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 47.9 Cg_endo -72.98 -20.02 22.5 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 O-C-N 124.049 1.552 . . . . 0.0 110.661 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.8 m -99.14 31.66 2.97 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.17 -0.956 . . . . 0.0 110.074 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.62 41.54 93.93 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 1.019 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -114.94 -172.74 2.18 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.174 -1.192 . . . . 0.0 110.336 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.506 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 20.3 m95 -140.04 147.95 41.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.927 . . . . 0.0 110.236 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 113.84 0.81 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.67 106.47 18.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -1.162 . . . . 0.0 109.993 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.8 m -119.21 139.39 27.46 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 110.232 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.47 148.22 47.86 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.017 1.535 . . . . 0.0 110.646 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 4.7 t80 . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.404 -0.81 . . . . 0.0 109.872 179.854 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.869 ' CG2' HD11 ' A' ' 9' ' ' ILE . 5.5 m . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.288 0.566 . . . . 0.0 110.309 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.831 HG12 ' O ' ' A' ' 10' ' ' CYS . 3.1 p -122.32 88.88 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.34 -0.85 . . . . 0.0 110.059 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.508 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -59.07 82.32 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 110.429 -179.71 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.479 ' N ' ' O ' ' A' ' 2' ' ' VAL . 0.4 OUTLIER -54.13 -28.46 39.88 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.189 -0.944 . . . . 0.0 109.817 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.91 -163.79 1.86 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.356 -0.84 . . . . 0.0 109.892 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -98.96 15.57 25.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.077 -1.014 . . . . 0.0 110.601 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.492 ' HG3' ' N ' ' A' ' 8' ' ' VAL . 11.1 pt-20 -136.61 -33.16 0.8 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.102 -0.999 . . . . 0.0 110.651 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.492 ' N ' ' HG3' ' A' ' 7' ' ' GLU . 9.4 p -116.49 162.44 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.085 -1.009 . . . . 0.0 110.401 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.869 HD11 ' CG2' ' A' ' 1' ' ' VAL . 3.5 tt -157.55 133.97 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.292 -0.88 . . . . 0.0 110.323 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.831 ' O ' HG12 ' A' ' 2' ' ' VAL . 51.2 m -107.73 144.18 28.78 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.082 -1.011 . . . . 0.0 109.589 179.489 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 13' ' ' GLY . 46.7 Cg_endo -80.33 38.01 0.72 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.675 1.355 . . . . 0.0 111.267 -179.738 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 3.0 t0 66.32 -56.33 0.38 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 110.859 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.22 -31.78 0.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . 0.515 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 47.5 m-85 -103.36 173.14 6.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.196 -1.179 . . . . 0.0 110.309 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.595 HG23 ' CD1' ' A' ' 29' ' ' PHE . 37.5 p -115.54 125.88 53.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.423 -0.798 . . . . 0.0 109.969 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 8.1 t -49.09 126.37 12.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 110.22 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.3 m -146.55 142.07 27.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 110.153 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.611 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -97.03 141.98 29.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 110.401 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.755 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -76.3 160.32 78.07 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 0.0 110.181 179.904 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.52 -6.97 20.06 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.985 1.518 . . . . 0.0 110.653 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 t -107.41 29.58 7.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 110.307 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.05 67.45 1.96 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.755 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -155.13 174.43 15.2 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -1.107 . . . . 0.0 110.148 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.611 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 14.6 m95 -123.06 147.63 46.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.237 -0.914 . . . . 0.0 110.252 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -165.94 155.24 26.38 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.496 ' HB3' ' HB2' ' A' ' 14' ' ' TYR . 7.8 m -98.33 125.75 43.58 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.223 -1.163 . . . . 0.0 109.862 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 1.1 m -109.61 129.45 23.91 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.156 -0.965 . . . . 0.0 110.397 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.78 155.15 54.03 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.782 1.411 . . . . 0.0 109.9 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.595 ' CD1' HG23 ' A' ' 15' ' ' THR . 4.6 p90 . . . . . 0 N--CA 1.49 1.573 0 O-C-N 121.124 -0.985 . . . . 0.0 110.859 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.545 ' HB ' ' CD1' ' A' ' 9' ' ' ILE . 6.9 m . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.31 0.576 . . . . 0.0 110.22 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.55 HG21 ' OD2' ' A' ' 12' ' ' ASP . 44.6 t -105.5 103.72 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 110.292 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.405 ' C ' ' O ' ' A' ' 2' ' ' VAL . 14.2 m-70 -44.02 118.75 1.55 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.186 -0.946 . . . . 0.0 110.493 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -79.93 -37.77 33.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.322 -0.861 . . . . 0.0 109.693 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -169.54 -80.08 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.451 -0.781 . . . . 0.0 110.276 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 9.4 tpp -146.15 -53.79 0.26 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.136 -0.977 . . . . 0.0 110.59 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -102.84 13.14 35.11 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.104 -0.997 . . . . 0.0 110.205 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -138.17 141.08 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.345 -0.847 . . . . 0.0 110.08 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.545 ' CD1' ' HB ' ' A' ' 1' ' ' VAL . 0.0 OUTLIER -145.15 127.96 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 110.004 -179.825 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.465 ' SG ' ' HB2' ' A' ' 14' ' ' TYR . 0.5 OUTLIER -118.65 154.85 52.74 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.053 -1.03 . . . . 0.0 110.297 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.478 ' O ' ' N ' ' A' ' 13' ' ' GLY . 48.0 Cg_endo -78.59 43.14 1.38 Allowed 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.964 1.508 . . . . 0.0 111.434 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.55 ' OD2' HG21 ' A' ' 2' ' ' VAL . 3.8 t70 65.05 -58.95 0.26 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 111.137 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.41 -26.48 0.22 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 28' ' ' PRO . 92.1 m-85 -100.87 153.43 19.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.952 -1.322 . . . . 0.0 110.955 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 1.081 HG22 ' O ' ' A' ' 27' ' ' CYS . 10.1 t -102.43 146.18 28.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 109.784 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -94.74 122.11 37.01 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.34 -0.85 . . . . 0.0 110.684 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -139.77 144.1 37.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.38 -0.825 . . . . 0.0 109.571 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.594 ' HG3' ' CH2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -92.34 134.76 34.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.511 -179.581 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.504 ' CG ' ' HD2' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -64.59 171.93 2.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.386 -0.821 . . . . 0.0 110.431 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.504 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 49.9 Cg_endo -76.2 1.55 8.17 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.062 1.559 . . . . 0.0 110.713 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 69.0 m -117.69 29.56 7.77 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.211 -0.93 . . . . 0.0 110.483 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.49 58.58 9.09 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.51 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . -145.56 168.29 20.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.299 -1.118 . . . . 0.0 109.857 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.594 ' CH2' ' HG3' ' A' ' 18' ' ' ARG . 2.0 m95 -105.14 147.6 27.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.126 -0.984 . . . . 0.0 110.203 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -154.02 133.63 4.0 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.19 128.31 48.75 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -1.157 . . . . 0.0 110.008 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 1.081 ' O ' HG22 ' A' ' 15' ' ' THR . 76.7 m -124.38 133.15 24.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 110.379 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.479 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 50.1 Cg_endo -75.48 149.8 35.28 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.867 1.456 . . . . 0.0 110.249 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.57 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 11.7 p90 . . . . . 0 N--CA 1.493 1.702 0 O-C-N 121.213 -0.93 . . . . 0.0 110.321 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 121.348 0.594 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 89.3 t -105.96 -25.34 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.94 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 56.07 93.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.333 -0.854 . . . . 0.0 110.348 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.3 m -61.93 -36.95 82.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.915 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -163.4 -153.61 0.25 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.298 -0.876 . . . . 0.0 110.332 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -80.82 -15.74 55.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.227 -0.92 . . . . 0.0 110.619 -179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -135.35 23.23 3.46 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.222 -0.924 . . . . 0.0 110.514 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 16.6 t -142.98 149.29 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.09 -1.006 . . . . 0.0 110.254 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 6.2 tt -163.04 143.22 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.228 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.449 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -119.94 168.98 9.18 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.864 . . . . 0.0 110.145 -179.918 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.3 Cg_endo -80.25 38.84 0.78 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 124.092 1.575 . . . . 0.0 111.198 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.456 ' HB2' ' O ' ' A' ' 11' ' ' PRO . 1.4 m-20 66.69 138.19 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 120.948 -1.095 . . . . 0.0 110.377 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.48 42.88 7.64 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . 0.421 ' CD1' ' HA ' ' A' ' 28' ' ' PRO . 22.0 m-85 -150.59 151.91 33.29 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.201 -1.176 . . . . 0.0 110.543 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.755 HG22 ' O ' ' A' ' 27' ' ' CYS . 5.7 t -104.98 146.68 28.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.803 . . . . 0.0 110.109 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.7 m -97.83 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.305 -0.872 . . . . 0.0 110.226 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.8 m -111.0 127.15 55.43 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.194 -0.941 . . . . 0.0 110.152 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.581 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -85.69 124.79 32.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.121 -0.987 . . . . 0.0 110.435 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.808 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -72.0 161.73 77.24 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.29 -0.881 . . . . 0.0 110.054 179.924 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -74.16 -5.83 17.56 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.951 1.501 . . . . 0.0 110.548 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 t -111.56 31.81 5.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.27 -0.894 . . . . 0.0 110.246 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.67 68.75 1.55 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.808 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -155.58 179.6 9.03 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.317 -1.108 . . . . 0.0 110.182 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 24.8 m95 -134.57 147.27 50.23 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -0.865 . . . . 0.0 110.18 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.8 133.31 6.31 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -97.25 112.56 24.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -1.166 . . . . 0.0 110.29 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.755 ' O ' HG22 ' A' ' 15' ' ' THR . 1.3 m -105.56 144.43 28.83 Favored Pre-proline 0 N--CA 1.493 1.675 0 O-C-N 121.309 -0.869 . . . . 0.0 110.067 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' CD1' ' A' ' 14' ' ' TYR . 44.0 Cg_endo -70.92 149.08 58.92 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.805 1.424 . . . . 0.0 110.717 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 1.8 t80 . . . . . 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 110.328 -179.93 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.403 HG23 HD11 ' A' ' 9' ' ' ILE . 20.0 m . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.202 0.525 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 85.4 t -107.69 146.78 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.298 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.434 ' O ' ' C ' ' A' ' 4' ' ' CYS . 10.9 t60 -70.56 80.78 0.58 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.2 -0.938 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.49 ' HB3' ' HB ' ' A' ' 8' ' ' VAL . 3.7 t -40.8 -52.98 2.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.395 -0.816 . . . . 0.0 110.536 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 1.2 t0 -145.46 -147.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.125 -0.985 . . . . 0.0 110.288 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -78.04 -33.81 50.82 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.227 -0.92 . . . . 0.0 110.444 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -126.93 20.47 7.0 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.107 -0.996 . . . . 0.0 110.471 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.49 ' HB ' ' HB3' ' A' ' 4' ' ' CYS . 16.3 t -126.8 152.52 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.282 -0.886 . . . . 0.0 109.931 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.707 ' O ' HG23 ' A' ' 9' ' ' ILE . 0.7 OUTLIER -146.04 105.82 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.095 -1.003 . . . . 0.0 110.825 -179.619 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 84.1 m -121.07 161.19 41.82 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.267 -0.895 . . . . 0.0 109.546 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.599 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 40.5 Cg_endo -72.71 154.99 54.49 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.787 1.414 . . . . 0.0 110.881 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -48.86 -19.16 0.35 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.564 -0.71 . . . . 0.0 111.544 -178.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.431 ' O ' ' CD1' ' A' ' 14' ' ' TYR . . . -87.24 32.27 4.17 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . 0.599 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 11.6 m-85 -140.78 162.35 35.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.064 -1.257 . . . . 0.0 110.833 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.924 HG22 ' O ' ' A' ' 27' ' ' CYS . 1.0 OUTLIER -128.99 118.27 22.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.519 -0.738 . . . . 0.0 109.419 179.482 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 130.44 40.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.375 -0.828 . . . . 0.0 110.863 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -144.02 131.17 20.65 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.704 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.41 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -81.4 132.26 35.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 110.21 -179.817 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.903 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -62.98 165.35 10.37 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.337 -0.852 . . . . 0.0 110.093 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.489 ' HD2' HD23 ' A' ' 19' ' ' LEU . 50.0 Cg_endo -80.01 41.58 1.15 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.955 1.503 . . . . 0.0 110.848 179.76 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -168.33 30.05 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.029 -1.044 . . . . 0.0 110.488 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.78 61.47 3.09 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.903 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -151.41 170.68 18.98 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.314 -1.109 . . . . 0.0 110.097 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.421 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 1.7 m95 -116.19 149.22 39.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.139 -0.975 . . . . 0.0 110.466 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.76 123.57 1.03 Allowed Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 15' ' ' THR . 26.3 p -97.28 130.09 44.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 110.235 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.924 ' O ' HG22 ' A' ' 15' ' ' THR . 0.0 OUTLIER -100.0 150.07 36.55 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.26 -0.9 . . . . 0.0 109.906 179.851 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.97 145.89 63.25 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.797 1.42 . . . . 0.0 110.58 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.528 -0.733 . . . . 0.0 109.982 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.501 ' HB ' HD11 ' A' ' 9' ' ' ILE . 17.1 m . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.16 0.505 . . . . 0.0 110.236 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . 0.586 ' O ' HG12 ' A' ' 2' ' ' VAL . 43.8 t -135.48 79.93 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.3 -0.875 . . . . 0.0 109.95 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.501 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -44.22 112.56 0.42 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.375 -0.828 . . . . 0.0 110.639 -179.663 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.574 ' HB2' HG12 ' A' ' 8' ' ' VAL . 1.6 m -73.54 -23.67 60.02 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.793 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.485 ' OD1' ' HB ' ' A' ' 8' ' ' VAL . 12.3 p-10 -160.18 -134.1 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.499 -0.751 . . . . 0.0 109.639 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' MET . . . . . 0.402 ' N ' ' CG ' ' A' ' 5' ' ' ASP . 0.0 OUTLIER -79.71 -42.47 24.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.886 -1.134 . . . . 0.0 110.131 179.81 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 8' ' ' VAL . 3.5 tp10 -121.83 -60.92 1.55 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.21 -0.931 . . . . 0.0 110.012 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.574 HG12 ' HB2' ' A' ' 4' ' ' CYS . 0.9 OUTLIER -42.22 126.4 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 110.072 -179.913 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.501 HD11 ' HB ' ' A' ' 1' ' ' VAL . 9.9 tt -152.22 144.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.307 -0.87 . . . . 0.0 109.949 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.434 ' SG ' ' CB ' ' A' ' 14' ' ' TYR . 0.1 OUTLIER -108.78 160.11 28.51 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.168 -0.958 . . . . 0.0 110.416 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.8 Cg_endo -78.98 42.77 1.34 Allowed 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 124.119 1.589 . . . . 0.0 111.044 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.457 ' OD1' HG23 ' A' ' 2' ' ' VAL . 10.4 m-20 63.04 137.91 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.925 -1.11 . . . . 0.0 110.248 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.67 3.46 56.18 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . 0.434 ' CB ' ' SG ' ' A' ' 10' ' ' CYS . 79.2 m-85 -125.06 165.07 18.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.196 -1.179 . . . . 0.0 110.26 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.821 HG22 ' O ' ' A' ' 27' ' ' CYS . 14.7 t -115.49 143.65 45.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.27 -0.894 . . . . 0.0 110.212 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.8 m -78.03 100.47 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.376 -0.828 . . . . 0.0 110.24 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.72 132.84 53.55 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.06 145.73 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.91 . . . . 0.0 110.145 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.88 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -80.86 165.88 42.63 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.306 -0.871 . . . . 0.0 110.115 179.99 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.425 ' HD2' ' HG ' ' A' ' 19' ' ' LEU . 46.5 Cg_endo -73.9 1.39 7.13 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.963 1.507 . . . . 0.0 110.798 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -118.98 32.25 6.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.171 -0.956 . . . . 0.0 110.047 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.94 41.83 95.16 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -120.45 -178.52 3.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.29 -1.124 . . . . 0.0 110.342 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -127.11 149.7 49.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.177 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -161.48 144.56 9.92 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -94.64 132.74 39.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.152 -1.205 . . . . 0.0 110.136 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . 0.821 ' O ' HG22 ' A' ' 15' ' ' THR . 13.8 m -121.75 144.99 42.06 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.118 -0.989 . . . . 0.0 110.222 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -73.45 151.48 47.84 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 123.936 1.492 . . . . 0.0 110.175 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.326 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.3 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.285 0.564 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 23.0 t -104.4 56.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 109.733 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.509 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 2.0 p-80 -47.25 128.64 12.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.396 -0.815 . . . . 0.0 110.602 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.8 m -81.93 -34.2 29.98 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.559 179.209 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -146.54 -60.61 0.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.447 -0.783 . . . . 0.0 110.092 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' MET . . . . . 0.53 ' HG3' ' N ' ' A' ' 7' ' ' GLU . 17.1 ptm -176.51 -36.03 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.393 -0.817 . . . . 0.0 109.809 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.53 ' N ' ' HG3' ' A' ' 6' ' ' MET . 6.4 tt0 -107.05 -49.91 3.19 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.384 -0.822 . . . . 0.0 109.891 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.6 t -86.39 104.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.275 -0.891 . . . . 0.0 109.624 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.476 HD13 ' C ' ' A' ' 9' ' ' ILE . 0.0 OUTLIER -123.89 158.94 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.938 . . . . 0.0 110.216 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -120.21 156.0 55.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.155 -0.966 . . . . 0.0 109.91 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.532 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 44.1 Cg_endo -82.09 32.98 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 123.764 1.402 . . . . 0.0 111.267 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 19.1 t0 66.59 -56.31 0.4 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.101 -0.999 . . . . 0.0 111.183 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.05 -23.71 0.45 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' TYR . . . . . 0.627 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 13.7 m-85 -112.92 173.08 6.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.276 . . . . 0.0 110.913 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 26' ' ' CYS . 4.4 p -106.46 135.19 48.4 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 25' ' ' GLY . 4.0 t -88.7 104.47 16.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.926 -1.109 . . . . 0.0 111.251 -178.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.1 p -106.76 139.33 41.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.447 -0.783 . . . . 0.0 109.207 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.578 ' HG3' ' CE2' ' A' ' 24' ' ' TRP . 7.1 ttt180 -77.81 137.56 38.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.001 -1.062 . . . . 0.0 110.809 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LEU . . . . . 0.898 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -73.96 177.86 1.9 Allowed Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.51 -0.744 . . . . 0.0 109.968 179.766 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.542 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 45.7 Cg_endo -72.73 -11.12 25.75 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.931 1.49 . . . . 0.0 110.408 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.9 t -108.83 28.47 8.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.181 -0.949 . . . . 0.0 110.133 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.08 12.07 79.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.898 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -85.62 -172.95 4.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.29 -1.123 . . . . 0.0 110.258 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.578 ' CE2' ' HG3' ' A' ' 18' ' ' ARG . 27.7 m95 -137.28 147.19 45.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.342 -0.849 . . . . 0.0 109.875 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 16' ' ' CYS . . . -143.79 151.99 23.81 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.486 ' HA ' ' O ' ' A' ' 15' ' ' THR . 7.5 m -108.58 107.02 17.35 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.298 -1.119 . . . . 0.0 110.08 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.78 132.88 23.01 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.185 -0.947 . . . . 0.0 109.945 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.52 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 44.4 Cg_endo -72.48 149.72 50.53 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 O-C-N 123.68 1.358 . . . . 0.0 110.783 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 3.0 t80 . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.386 -0.821 . . . . 0.0 110.229 -179.977 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.925 HG21 HD11 ' A' ' 9' ' ' ILE . 10.8 m . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 121.248 0.547 . . . . 0.0 110.275 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' A' ' 4' ' ' CYS . 23.4 t -99.08 82.6 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.249 -0.907 . . . . 0.0 110.086 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.511 ' ND1' ' N ' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -51.59 89.77 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.182 -0.949 . . . . 0.0 110.476 -179.79 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.492 ' N ' ' O ' ' A' ' 2' ' ' VAL . 88.8 m -60.14 -19.46 53.81 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.214 -0.929 . . . . 0.0 109.91 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.451 ' HB2' ' O ' ' A' ' 4' ' ' CYS . 1.8 t0 177.9 -170.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.517 -0.739 . . . . 0.0 109.841 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 12.5 mtt -91.75 14.08 16.36 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.078 -1.014 . . . . 0.0 110.436 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -127.78 3.02 6.05 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.283 -0.886 . . . . 0.0 110.056 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.425 HG13 ' HB2' ' A' ' 4' ' ' CYS . 8.5 p -168.48 154.44 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.37 -0.831 . . . . 0.0 110.098 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.925 HD11 HG21 ' A' ' 1' ' ' VAL . 8.8 tt -146.39 125.52 5.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.226 -0.921 . . . . 0.0 110.032 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.461 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 67.3 m -127.95 137.16 30.2 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.18 -0.95 . . . . 0.0 110.219 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.614 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 43.1 Cg_endo -73.06 152.88 51.73 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.838 1.441 . . . . 0.0 110.595 179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.457 ' OD1' ' N ' ' A' ' 13' ' ' GLY . 0.6 OUTLIER -37.24 -44.47 0.58 Allowed 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.719 -0.613 . . . . 0.0 111.487 -179.606 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.457 ' N ' ' OD1' ' A' ' 12' ' ' ASP . . . -62.58 -3.42 5.54 Favored Glycine 0 N--CA 1.493 2.491 0 C-N-CA 120.488 -0.863 . . . . 0.0 111.7 -178.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . 0.614 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 17.9 m-85 -124.26 154.26 40.48 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 120.445 -1.621 . . . . 0.0 111.52 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 17.5 p -107.34 137.65 44.99 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.534 -0.728 . . . . 0.0 109.778 179.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.76 142.38 27.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.21 -0.931 . . . . 0.0 110.33 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -135.96 149.21 48.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.302 -0.873 . . . . 0.0 109.983 179.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.589 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -103.63 129.41 50.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.155 -0.966 . . . . 0.0 110.188 -179.957 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.974 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -69.78 168.61 16.51 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.914 . . . . 0.0 110.128 -179.94 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.59 ' HD2' HD23 ' A' ' 19' ' ' LEU . 46.6 Cg_endo -74.7 2.17 6.75 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 124.009 1.531 . . . . 0.0 110.695 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -122.53 33.27 5.49 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.088 -1.008 . . . . 0.0 110.417 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.53 30.24 73.06 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.974 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -108.27 -174.14 2.45 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.248 -1.148 . . . . 0.0 110.272 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.589 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 31.7 m95 -137.84 147.88 44.93 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.288 -0.883 . . . . 0.0 110.276 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -143.72 156.34 26.58 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.8 t -118.75 135.57 54.43 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.232 -1.158 . . . . 0.0 110.527 -179.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -139.61 125.49 11.99 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.281 -0.887 . . . . 0.0 109.999 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.32 164.81 34.23 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 123.787 1.414 . . . . 0.0 110.354 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -119.84 45.01 2.26 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.243 -0.91 . . . . 0.0 110.222 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 3.2 p -106.76 85.26 2.13 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.252 -0.905 . . . . 0.0 110.222 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 4.5 mt-30 . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.891 . . . . 0.0 110.249 179.982 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.597 HG12 ' H ' ' A' ' 2' ' ' VAL . 1.4 t . . . . . 0 N--CA 1.493 1.695 0 CA-C-O 121.148 0.499 . . . . 0.0 109.692 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.761 HG22 ' O ' ' A' ' 10' ' ' CYS . 24.9 m -112.43 80.25 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.07 -1.019 . . . . 0.0 110.108 179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.409 ' C ' ' O ' ' A' ' 2' ' ' VAL . 1.4 m-70 -42.83 125.63 3.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.298 -0.876 . . . . 0.0 110.3 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.414 ' HB3' HG12 ' A' ' 8' ' ' VAL . 0.1 OUTLIER -101.67 -40.0 7.19 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.274 -0.891 . . . . 0.0 110.053 179.667 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.0 m-20 -145.46 -166.91 2.55 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.32 -0.862 . . . . 0.0 110.017 179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 4.0 tmm? -61.21 -50.19 74.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.155 -0.966 . . . . 0.0 110.244 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.582 ' O ' HG23 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -126.17 61.22 1.28 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.322 -0.861 . . . . 0.0 110.293 -179.824 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 7' ' ' GLU . 1.0 OUTLIER -167.19 119.62 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.269 -0.894 . . . . 0.0 109.696 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 10' ' ' CYS . 3.4 mt -131.62 162.32 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.182 -0.949 . . . . 0.0 110.666 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.761 ' O ' HG22 ' A' ' 2' ' ' VAL . 0.1 OUTLIER -136.28 136.31 22.31 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.275 -0.89 . . . . 0.0 109.57 179.523 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.66 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 42.5 Cg_endo -71.27 53.79 1.7 Allowed 'Trans proline' 0 C--N 1.307 -1.616 0 O-C-N 123.753 1.396 . . . . 0.0 111.656 -179.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.509 ' O ' ' N ' ' A' ' 14' ' ' TYR . 19.0 t0 54.12 -77.57 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.59 -0.694 . . . . 0.0 111.808 178.598 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.543 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -37.16 -28.93 0.03 OUTLIER Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . 0.66 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 24.9 m-85 -92.0 161.88 14.61 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.118 -1.225 . . . . 0.0 110.657 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.514 HG22 ' O ' ' A' ' 27' ' ' CYS . 0.6 OUTLIER -119.78 145.2 46.8 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.369 -0.832 . . . . 0.0 110.04 179.884 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.2 m -80.22 140.52 36.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.338 -0.851 . . . . 0.0 110.358 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.62 117.14 6.56 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.256 -0.903 . . . . 0.0 110.119 179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -72.06 149.34 44.96 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.121 -0.987 . . . . 0.0 109.979 179.98 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.513 HD23 ' HD2' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -89.36 170.4 10.84 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.188 -0.945 . . . . 0.0 110.566 -179.627 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.513 ' HD2' HD23 ' A' ' 19' ' ' LEU . 46.3 Cg_endo -73.07 -3.66 14.05 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 124.054 1.555 . . . . 0.0 110.277 179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 5.5 m -109.33 25.64 11.56 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.299 -0.876 . . . . 0.0 110.038 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.39 51.54 42.28 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.508 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -136.95 -173.2 3.38 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.179 -1.189 . . . . 0.0 110.237 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -120.85 148.31 44.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.226 -0.921 . . . . 0.0 110.436 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -152.74 125.52 1.82 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -96.99 130.24 44.34 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.286 -1.126 . . . . 0.0 109.716 179.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.514 ' O ' HG22 ' A' ' 15' ' ' THR . 95.6 m -126.88 153.11 76.14 Favored Pre-proline 0 N--CA 1.493 1.707 0 O-C-N 121.149 -0.97 . . . . 0.0 110.568 -179.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.93 151.85 51.14 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.12 1.589 . . . . 0.0 110.266 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -121.17 149.12 43.28 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.262 -0.899 . . . . 0.0 110.44 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -136.77 82.09 1.92 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.394 -0.816 . . . . 0.0 110.031 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.6 0 O-C-N 121.297 -0.877 . . . . 0.0 110.268 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.569 HG12 HG23 ' A' ' 2' ' ' VAL . 73.1 t . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.254 0.549 . . . . 0.0 110.2 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.569 HG23 HG12 ' A' ' 1' ' ' VAL . 22.0 t -97.66 72.34 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.145 -0.972 . . . . 0.0 109.86 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.502 ' CE1' HG21 ' A' ' 9' ' ' ILE . 24.8 m-70 -46.05 106.67 0.08 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.339 -0.851 . . . . 0.0 110.668 -179.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.497 ' HB3' ' O ' ' A' ' 8' ' ' VAL . 7.1 t -89.01 -25.64 21.88 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.259 -0.901 . . . . 0.0 109.632 179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.9 t0 -156.87 -139.71 0.08 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.386 -0.821 . . . . 0.0 109.764 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 55.1 mtm -79.82 -50.5 10.44 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.1 -1.0 . . . . 0.0 110.023 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -122.89 -1.31 8.89 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.29 -0.881 . . . . 0.0 110.22 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.497 ' O ' ' HB3' ' A' ' 4' ' ' CYS . 45.0 t -89.97 75.77 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.187 -0.946 . . . . 0.0 110.252 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.502 HG21 ' CE1' ' A' ' 3' ' ' HIS . 6.8 pt -112.07 126.82 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.058 -1.026 . . . . 0.0 109.997 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -109.95 157.92 36.44 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.28 -0.887 . . . . 0.0 110.172 -179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.473 ' O ' ' N ' ' A' ' 13' ' ' GLY . 48.2 Cg_endo -81.15 41.06 1.08 Allowed 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 123.873 1.46 . . . . 0.0 110.944 179.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.54 ' OD1' HG21 ' A' ' 2' ' ' VAL . 0.3 OUTLIER 66.34 -57.97 0.36 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.051 -1.031 . . . . 0.0 110.817 179.528 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.473 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.0 -25.02 0.59 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . 0.469 ' CD1' ' HD2' ' A' ' 11' ' ' PRO . 54.3 m-85 -96.04 163.66 13.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.035 -1.274 . . . . 0.0 110.826 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.749 HG22 ' O ' ' A' ' 27' ' ' CYS . 0.7 OUTLIER -113.62 131.14 56.23 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.473 -0.767 . . . . 0.0 109.459 179.018 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 2.4 t -90.54 102.38 15.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.518 -0.739 . . . . 0.0 110.373 -179.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -112.25 137.57 50.17 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.209 -0.932 . . . . 0.0 109.836 179.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 4.2 mtm105 -92.11 131.86 37.05 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.196 -0.94 . . . . 0.0 110.055 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.587 HD23 ' HD2' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -67.67 165.76 27.96 Favored Pre-proline 0 N--CA 1.489 1.507 0 O-C-N 121.335 -0.853 . . . . 0.0 110.138 179.977 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.587 ' HD2' HD23 ' A' ' 19' ' ' LEU . 43.9 Cg_endo -69.62 -5.29 15.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.962 1.507 . . . . 0.0 110.325 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -102.15 26.99 7.03 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.413 -0.804 . . . . 0.0 110.113 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.83 27.23 72.55 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -109.38 171.0 7.7 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.13 -1.218 . . . . 0.0 110.389 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 8.1 m95 -111.2 150.51 29.44 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.304 -0.872 . . . . 0.0 109.864 179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -151.76 109.27 0.41 Allowed Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.624 -1.274 . . . . 0.0 110.086 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER -93.52 115.94 28.46 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.214 -1.168 . . . . 0.0 109.65 179.222 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.749 ' O ' HG22 ' A' ' 15' ' ' THR . 25.0 p -129.93 153.2 80.93 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.135 -0.978 . . . . 0.0 110.586 -179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -72.82 149.84 48.64 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.045 1.55 . . . . 0.0 110.244 179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.547 ' CD2' ' O ' ' A' ' 29' ' ' PHE . 72.4 t80 -147.63 59.84 1.14 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.23 -179.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.755 ' O ' HG23 ' A' ' 30' ' ' THR . 15.3 t -116.18 69.92 0.75 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.251 -0.906 . . . . 0.0 110.254 -179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? . . . . . 0 N--CA 1.492 1.652 0 O-C-N 121.18 -0.95 . . . . 0.0 110.116 179.904 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.421 HG13 ' H3 ' ' A' ' 1' ' ' VAL . 28.4 m . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.236 0.541 . . . . 0.0 110.327 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.507 ' HB ' ' O ' ' A' ' 10' ' ' CYS . 21.0 t -108.04 100.82 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.235 -0.916 . . . . 0.0 110.117 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 22.8 m-70 -81.53 89.84 6.21 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.197 -0.939 . . . . 0.0 110.105 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 44.9 m -84.74 4.45 32.69 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.21 -0.931 . . . . 0.0 110.381 -179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -168.88 -166.45 0.65 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.19 -0.944 . . . . 0.0 110.359 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 24.2 mtm -97.07 -27.15 14.72 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.249 -0.907 . . . . 0.0 110.603 -179.688 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.9 mm-40 -108.41 -47.83 3.44 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.098 -1.001 . . . . 0.0 110.769 -179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.484 ' C ' ' CG2' ' A' ' 9' ' ' ILE . 0.3 OUTLIER -90.09 137.93 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.097 -1.002 . . . . 0.0 110.27 -179.821 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.484 ' CG2' ' C ' ' A' ' 8' ' ' VAL . 4.4 pt -151.2 131.19 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.258 -0.901 . . . . 0.0 110.092 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.507 ' O ' ' HB ' ' A' ' 2' ' ' VAL . 20.5 m -122.71 162.68 37.25 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 109.957 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -82.93 173.34 10.27 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.736 1.388 . . . . 0.0 110.564 179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -63.79 -19.22 64.83 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.288 -0.883 . . . . 0.0 111.217 -179.107 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.14 -4.91 38.39 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.963 -1.255 . . . . 0.0 109.963 -179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -132.24 175.16 9.5 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.032 -1.275 . . . . 0.0 110.956 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 7.0 p -128.56 119.01 24.0 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.626 -0.671 . . . . 0.0 109.331 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.419 ' O ' ' SG ' ' A' ' 16' ' ' CYS . 28.9 p -82.15 123.47 29.01 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.241 -0.912 . . . . 0.0 110.654 -179.287 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.2 m -118.05 127.4 53.77 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.506 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -82.37 122.68 28.3 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.186 -0.946 . . . . 0.0 110.331 -179.787 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 1.019 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -67.66 170.37 7.2 Favored Pre-proline 0 N--CA 1.492 1.664 0 O-C-N 121.295 -0.878 . . . . 0.0 110.175 179.988 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.523 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 47.9 Cg_endo -72.98 -20.02 22.5 Favored 'Trans proline' 0 C--N 1.305 -1.746 0 O-C-N 124.049 1.552 . . . . 0.0 110.661 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 1.8 m -99.14 31.66 2.97 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.17 -0.956 . . . . 0.0 110.074 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.62 41.54 93.93 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 1.019 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -114.94 -172.74 2.18 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.174 -1.192 . . . . 0.0 110.336 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.506 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 20.3 m95 -140.04 147.95 41.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.218 -0.927 . . . . 0.0 110.236 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -142.95 113.84 0.81 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.354 -1.498 . . . . 0.0 109.354 179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 1.5 m -92.67 106.47 18.44 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.224 -1.162 . . . . 0.0 109.993 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 79.8 m -119.21 139.39 27.46 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.236 -0.915 . . . . 0.0 110.232 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.47 148.22 47.86 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.017 1.535 . . . . 0.0 110.646 -179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 4.7 t80 -72.57 110.95 7.31 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.404 -0.81 . . . . 0.0 109.872 179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 1.6 t -134.27 63.07 1.63 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.285 -0.884 . . . . 0.0 110.159 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 5.4 mp0 . . . . . 0 N--CA 1.49 1.547 0 O-C-N 121.218 -0.926 . . . . 0.0 110.269 -179.931 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.869 ' CG2' HD11 ' A' ' 9' ' ' ILE . 5.5 m . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.288 0.566 . . . . 0.0 110.309 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.831 HG12 ' O ' ' A' ' 10' ' ' CYS . 3.1 p -122.32 88.88 1.33 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.34 -0.85 . . . . 0.0 110.059 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.508 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 0.0 OUTLIER -59.07 82.32 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.196 -0.94 . . . . 0.0 110.429 -179.71 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.479 ' N ' ' O ' ' A' ' 2' ' ' VAL . 0.4 OUTLIER -54.13 -28.46 39.88 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.189 -0.944 . . . . 0.0 109.817 179.799 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -147.91 -163.79 1.86 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.356 -0.84 . . . . 0.0 109.892 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -98.96 15.57 25.28 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.077 -1.014 . . . . 0.0 110.601 -179.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.492 ' HG3' ' N ' ' A' ' 8' ' ' VAL . 11.1 pt-20 -136.61 -33.16 0.8 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.102 -0.999 . . . . 0.0 110.651 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.492 ' N ' ' HG3' ' A' ' 7' ' ' GLU . 9.4 p -116.49 162.44 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.085 -1.009 . . . . 0.0 110.401 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.869 HD11 ' CG2' ' A' ' 1' ' ' VAL . 3.5 tt -157.55 133.97 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.292 -0.88 . . . . 0.0 110.323 -179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.831 ' O ' HG12 ' A' ' 2' ' ' VAL . 51.2 m -107.73 144.18 28.78 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.082 -1.011 . . . . 0.0 109.589 179.489 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.49 ' O ' ' N ' ' A' ' 13' ' ' GLY . 46.7 Cg_endo -80.33 38.01 0.72 Allowed 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 123.675 1.355 . . . . 0.0 111.267 -179.738 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.462 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 3.0 t0 66.32 -56.33 0.38 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.044 -1.035 . . . . 0.0 110.859 179.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.22 -31.78 0.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . 0.515 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 47.5 m-85 -103.36 173.14 6.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.196 -1.179 . . . . 0.0 110.309 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.595 HG23 ' CD1' ' A' ' 29' ' ' PHE . 37.5 p -115.54 125.88 53.55 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.423 -0.798 . . . . 0.0 109.969 179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 8.1 t -49.09 126.37 12.45 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.392 -0.818 . . . . 0.0 110.22 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 1.3 m -146.55 142.07 27.63 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.22 -0.925 . . . . 0.0 110.153 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.611 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -97.03 141.98 29.53 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.276 -0.89 . . . . 0.0 110.401 -179.851 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.755 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.3 OUTLIER -76.3 160.32 78.07 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.323 -0.861 . . . . 0.0 110.181 179.904 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.52 -6.97 20.06 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 O-C-N 123.985 1.518 . . . . 0.0 110.653 -179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 3.2 t -107.41 29.58 7.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 110.307 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 68.05 67.45 1.96 Allowed Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.755 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -155.13 174.43 15.2 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.318 -1.107 . . . . 0.0 110.148 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.611 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 14.6 m95 -123.06 147.63 46.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.237 -0.914 . . . . 0.0 110.252 179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -165.94 155.24 26.38 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.496 ' HB3' ' HB2' ' A' ' 14' ' ' TYR . 7.8 m -98.33 125.75 43.58 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.223 -1.163 . . . . 0.0 109.862 179.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 1.1 m -109.61 129.45 23.91 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.156 -0.965 . . . . 0.0 110.397 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.78 155.15 54.03 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.782 1.411 . . . . 0.0 109.9 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.806 ' CE2' HG22 ' A' ' 30' ' ' THR . 4.6 p90 -147.66 -45.42 0.17 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.124 -0.985 . . . . 0.0 110.859 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.806 HG22 ' CE2' ' A' ' 29' ' ' PHE . 3.7 t -139.57 52.83 1.71 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.932 -1.105 . . . . 0.0 110.625 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 18.7 mt-30 . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.036 -1.04 . . . . 0.0 110.205 179.807 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.545 ' HB ' ' CD1' ' A' ' 9' ' ' ILE . 6.9 m . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.31 0.576 . . . . 0.0 110.22 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.55 HG21 ' OD2' ' A' ' 12' ' ' ASP . 44.6 t -105.5 103.72 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.273 -0.892 . . . . 0.0 110.292 -179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.405 ' C ' ' O ' ' A' ' 2' ' ' VAL . 14.2 m-70 -44.02 118.75 1.55 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.186 -0.946 . . . . 0.0 110.493 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -79.93 -37.77 33.85 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.322 -0.861 . . . . 0.0 109.693 179.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -169.54 -80.08 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.451 -0.781 . . . . 0.0 110.276 179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 9.4 tpp -146.15 -53.79 0.26 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.136 -0.977 . . . . 0.0 110.59 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -102.84 13.14 35.11 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.104 -0.997 . . . . 0.0 110.205 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -138.17 141.08 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.345 -0.847 . . . . 0.0 110.08 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.545 ' CD1' ' HB ' ' A' ' 1' ' ' VAL . 0.0 OUTLIER -145.15 127.96 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.321 -0.862 . . . . 0.0 110.004 -179.825 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.465 ' SG ' ' HB2' ' A' ' 14' ' ' TYR . 0.5 OUTLIER -118.65 154.85 52.74 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.053 -1.03 . . . . 0.0 110.297 -179.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.478 ' O ' ' N ' ' A' ' 13' ' ' GLY . 48.0 Cg_endo -78.59 43.14 1.38 Allowed 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.964 1.508 . . . . 0.0 111.434 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.55 ' OD2' HG21 ' A' ' 2' ' ' VAL . 3.8 t70 65.05 -58.95 0.26 Allowed 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.132 -0.98 . . . . 0.0 111.137 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -41.41 -26.48 0.22 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . 0.479 ' CE2' ' HB3' ' A' ' 28' ' ' PRO . 92.1 m-85 -100.87 153.43 19.5 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.952 -1.322 . . . . 0.0 110.955 -179.422 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 1.081 HG22 ' O ' ' A' ' 27' ' ' CYS . 10.1 t -102.43 146.18 28.45 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 109.784 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -94.74 122.11 37.01 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.34 -0.85 . . . . 0.0 110.684 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -139.77 144.1 37.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.38 -0.825 . . . . 0.0 109.571 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.594 ' HG3' ' CH2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -92.34 134.76 34.62 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.173 -0.954 . . . . 0.0 110.511 -179.581 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.504 ' CG ' ' HD2' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -64.59 171.93 2.5 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.386 -0.821 . . . . 0.0 110.431 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.504 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 49.9 Cg_endo -76.2 1.55 8.17 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.062 1.559 . . . . 0.0 110.713 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 69.0 m -117.69 29.56 7.77 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.211 -0.93 . . . . 0.0 110.483 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.49 58.58 9.09 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.51 ' O ' ' HA ' ' A' ' 18' ' ' ARG . . . -145.56 168.29 20.97 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.299 -1.118 . . . . 0.0 109.857 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.594 ' CH2' ' HG3' ' A' ' 18' ' ' ARG . 2.0 m95 -105.14 147.6 27.78 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.126 -0.984 . . . . 0.0 110.203 179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -154.02 133.63 4.0 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -102.19 128.31 48.75 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.232 -1.157 . . . . 0.0 110.008 179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 1.081 ' O ' HG22 ' A' ' 15' ' ' THR . 76.7 m -124.38 133.15 24.49 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 110.379 -179.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.479 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 50.1 Cg_endo -75.48 149.8 35.28 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.867 1.456 . . . . 0.0 110.249 179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.57 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 11.7 p90 -134.39 140.9 46.63 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.213 -0.93 . . . . 0.0 110.321 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 15.9 m -89.29 157.15 18.32 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.283 -0.885 . . . . 0.0 110.097 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.211 -0.931 . . . . 0.0 110.18 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 121.348 0.594 . . . . 0.0 110.206 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 89.3 t -105.96 -25.34 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.225 -0.922 . . . . 0.0 109.94 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 56.07 93.5 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.333 -0.854 . . . . 0.0 110.348 179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 1.3 m -61.93 -36.95 82.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.274 -0.891 . . . . 0.0 109.915 179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -163.4 -153.61 0.25 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.298 -0.876 . . . . 0.0 110.332 179.779 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -80.82 -15.74 55.59 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.227 -0.92 . . . . 0.0 110.619 -179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -135.35 23.23 3.46 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.222 -0.924 . . . . 0.0 110.514 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 16.6 t -142.98 149.29 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.09 -1.006 . . . . 0.0 110.254 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 6.2 tt -163.04 143.22 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.28 -0.888 . . . . 0.0 110.228 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.449 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -119.94 168.98 9.18 Favored Pre-proline 0 N--CA 1.491 1.616 0 O-C-N 121.317 -0.864 . . . . 0.0 110.145 -179.918 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.456 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.3 Cg_endo -80.25 38.84 0.78 Allowed 'Trans proline' 0 C--N 1.305 -1.742 0 O-C-N 124.092 1.575 . . . . 0.0 111.198 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.456 ' HB2' ' O ' ' A' ' 11' ' ' PRO . 1.4 m-20 66.69 138.19 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 120.948 -1.095 . . . . 0.0 110.377 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.48 42.88 7.64 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . 0.421 ' CD1' ' HA ' ' A' ' 28' ' ' PRO . 22.0 m-85 -150.59 151.91 33.29 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.201 -1.176 . . . . 0.0 110.543 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.755 HG22 ' O ' ' A' ' 27' ' ' CYS . 5.7 t -104.98 146.68 28.7 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.803 . . . . 0.0 110.109 179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 6.7 m -97.83 115.4 27.99 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.305 -0.872 . . . . 0.0 110.226 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 61.8 m -111.0 127.15 55.43 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.194 -0.941 . . . . 0.0 110.152 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.581 ' HG3' ' CZ2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -85.69 124.79 32.61 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.121 -0.987 . . . . 0.0 110.435 -179.867 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.808 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -72.0 161.73 77.24 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.29 -0.881 . . . . 0.0 110.054 179.924 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -74.16 -5.83 17.56 Favored 'Trans proline' 0 C--N 1.305 -1.719 0 O-C-N 123.951 1.501 . . . . 0.0 110.548 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 2.0 t -111.56 31.81 5.87 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.27 -0.894 . . . . 0.0 110.246 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.67 68.75 1.55 Allowed Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.808 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -155.58 179.6 9.03 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.317 -1.108 . . . . 0.0 110.182 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.581 ' CZ2' ' HG3' ' A' ' 18' ' ' ARG . 24.8 m95 -134.57 147.27 50.23 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -0.865 . . . . 0.0 110.18 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -137.8 133.31 6.31 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -97.25 112.56 24.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.217 -1.166 . . . . 0.0 110.29 -179.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.755 ' O ' HG22 ' A' ' 15' ' ' THR . 1.3 m -105.56 144.43 28.83 Favored Pre-proline 0 N--CA 1.493 1.675 0 O-C-N 121.309 -0.869 . . . . 0.0 110.067 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.421 ' HA ' ' CD1' ' A' ' 14' ' ' TYR . 44.0 Cg_endo -70.92 149.08 58.92 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.805 1.424 . . . . 0.0 110.717 -179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -153.6 20.56 0.54 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.249 -0.907 . . . . 0.0 110.328 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 34.6 p -103.88 31.17 4.64 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.186 -0.946 . . . . 0.0 110.409 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.9 pt20 . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.169 -0.957 . . . . 0.0 110.182 -179.995 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.403 HG23 HD11 ' A' ' 9' ' ' ILE . 20.0 m . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.202 0.525 . . . . 0.0 110.271 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 85.4 t -107.69 146.78 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.298 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.434 ' O ' ' C ' ' A' ' 4' ' ' CYS . 10.9 t60 -70.56 80.78 0.58 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.2 -0.938 . . . . 0.0 109.96 179.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.49 ' HB3' ' HB ' ' A' ' 8' ' ' VAL . 3.7 t -40.8 -52.98 2.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.395 -0.816 . . . . 0.0 110.536 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.427 ' O ' ' CD2' ' A' ' 3' ' ' HIS . 1.2 t0 -145.46 -147.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.125 -0.985 . . . . 0.0 110.288 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -78.04 -33.81 50.82 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.227 -0.92 . . . . 0.0 110.444 -179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -126.93 20.47 7.0 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.107 -0.996 . . . . 0.0 110.471 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.49 ' HB ' ' HB3' ' A' ' 4' ' ' CYS . 16.3 t -126.8 152.52 34.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.282 -0.886 . . . . 0.0 109.931 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.707 ' O ' HG23 ' A' ' 9' ' ' ILE . 0.7 OUTLIER -146.04 105.82 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.095 -1.003 . . . . 0.0 110.825 -179.619 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 84.1 m -121.07 161.19 41.82 Favored Pre-proline 0 N--CA 1.492 1.625 0 O-C-N 121.267 -0.895 . . . . 0.0 109.546 179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.599 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 40.5 Cg_endo -72.71 154.99 54.49 Favored 'Trans proline' 0 C--N 1.306 -1.697 0 O-C-N 123.787 1.414 . . . . 0.0 110.881 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -48.86 -19.16 0.35 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.564 -0.71 . . . . 0.0 111.544 -178.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.431 ' O ' ' CD1' ' A' ' 14' ' ' TYR . . . -87.24 32.27 4.17 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 -179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . 0.599 ' CD1' ' HG2' ' A' ' 11' ' ' PRO . 11.6 m-85 -140.78 162.35 35.64 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.064 -1.257 . . . . 0.0 110.833 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.924 HG22 ' O ' ' A' ' 27' ' ' CYS . 1.0 OUTLIER -128.99 118.27 22.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.519 -0.738 . . . . 0.0 109.419 179.482 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.71 130.44 40.54 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.375 -0.828 . . . . 0.0 110.863 -179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -144.02 131.17 20.65 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.405 -0.809 . . . . 0.0 109.704 179.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.41 ' HA ' ' O ' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -81.4 132.26 35.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.242 -0.911 . . . . 0.0 110.21 -179.817 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.903 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.0 OUTLIER -62.98 165.35 10.37 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.337 -0.852 . . . . 0.0 110.093 179.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.489 ' HD2' HD23 ' A' ' 19' ' ' LEU . 50.0 Cg_endo -80.01 41.58 1.15 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.955 1.503 . . . . 0.0 110.848 179.76 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -168.33 30.05 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.029 -1.044 . . . . 0.0 110.488 179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.78 61.47 3.09 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.903 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -151.41 170.68 18.98 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.314 -1.109 . . . . 0.0 110.097 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.421 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 1.7 m95 -116.19 149.22 39.45 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.139 -0.975 . . . . 0.0 110.466 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.76 123.57 1.03 Allowed Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 15' ' ' THR . 26.3 p -97.28 130.09 44.51 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.261 -1.141 . . . . 0.0 110.235 -179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.924 ' O ' HG22 ' A' ' 15' ' ' THR . 0.0 OUTLIER -100.0 150.07 36.55 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.26 -0.9 . . . . 0.0 109.906 179.851 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -68.97 145.89 63.25 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.797 1.42 . . . . 0.0 110.58 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -87.83 119.81 28.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.528 -0.733 . . . . 0.0 109.982 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.2 t -143.26 37.65 1.39 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.296 -0.878 . . . . 0.0 110.169 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 O-C-N 121.262 -0.899 . . . . 0.0 110.062 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.501 ' HB ' HD11 ' A' ' 9' ' ' ILE . 17.1 m . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.16 0.505 . . . . 0.0 110.236 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.586 ' O ' HG12 ' A' ' 2' ' ' VAL . 43.8 t -135.48 79.93 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.3 -0.875 . . . . 0.0 109.95 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.501 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 0.1 OUTLIER -44.22 112.56 0.42 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.375 -0.828 . . . . 0.0 110.639 -179.663 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.574 ' HB2' HG12 ' A' ' 8' ' ' VAL . 1.6 m -73.54 -23.67 60.02 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.273 -0.892 . . . . 0.0 109.793 179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.485 ' OD1' ' HB ' ' A' ' 8' ' ' VAL . 12.3 p-10 -160.18 -134.1 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.499 -0.751 . . . . 0.0 109.639 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' MET . . . . . 0.402 ' N ' ' CG ' ' A' ' 5' ' ' ASP . 0.0 OUTLIER -79.71 -42.47 24.59 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.886 -1.134 . . . . 0.0 110.131 179.81 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.427 ' O ' ' C ' ' A' ' 8' ' ' VAL . 3.5 tp10 -121.83 -60.92 1.55 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.21 -0.931 . . . . 0.0 110.012 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.574 HG12 ' HB2' ' A' ' 4' ' ' CYS . 0.9 OUTLIER -42.22 126.4 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.3 -0.875 . . . . 0.0 110.072 -179.913 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.501 HD11 ' HB ' ' A' ' 1' ' ' VAL . 9.9 tt -152.22 144.91 15.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.307 -0.87 . . . . 0.0 109.949 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.434 ' SG ' ' CB ' ' A' ' 14' ' ' TYR . 0.1 OUTLIER -108.78 160.11 28.51 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.168 -0.958 . . . . 0.0 110.416 -179.772 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 12' ' ' ASP . 50.8 Cg_endo -78.98 42.77 1.34 Allowed 'Trans proline' 0 C--N 1.306 -1.688 0 O-C-N 124.119 1.589 . . . . 0.0 111.044 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.457 ' OD1' HG23 ' A' ' 2' ' ' VAL . 10.4 m-20 63.04 137.91 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.321 0 O-C-N 120.925 -1.11 . . . . 0.0 110.248 179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 99.67 3.46 56.18 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . 0.434 ' CB ' ' SG ' ' A' ' 10' ' ' CYS . 79.2 m-85 -125.06 165.07 18.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.196 -1.179 . . . . 0.0 110.26 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.821 HG22 ' O ' ' A' ' 27' ' ' CYS . 14.7 t -115.49 143.65 45.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.27 -0.894 . . . . 0.0 110.212 179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 17.8 m -78.03 100.47 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.376 -0.828 . . . . 0.0 110.24 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -108.72 132.84 53.55 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -94.06 145.73 24.46 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.243 -0.91 . . . . 0.0 110.145 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.88 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.1 OUTLIER -80.86 165.88 42.63 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.306 -0.871 . . . . 0.0 110.115 179.99 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.425 ' HD2' ' HG ' ' A' ' 19' ' ' LEU . 46.5 Cg_endo -73.9 1.39 7.13 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 123.963 1.507 . . . . 0.0 110.798 -179.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -118.98 32.25 6.23 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.171 -0.956 . . . . 0.0 110.047 179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 65.94 41.83 95.16 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.88 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -120.45 -178.52 3.72 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.29 -1.124 . . . . 0.0 110.342 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -127.11 149.7 49.82 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.239 -0.913 . . . . 0.0 110.177 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -161.48 144.56 9.92 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -94.64 132.74 39.04 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.152 -1.205 . . . . 0.0 110.136 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . 0.821 ' O ' HG22 ' A' ' 15' ' ' THR . 13.8 m -121.75 144.99 42.06 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.118 -0.989 . . . . 0.0 110.222 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -73.45 151.48 47.84 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 123.936 1.492 . . . . 0.0 110.175 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -158.53 53.74 0.43 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.237 -0.914 . . . . 0.0 110.326 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 13.0 t -114.14 31.4 6.6 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.37 -0.831 . . . . 0.0 109.95 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 10.4 mm-40 . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.234 -0.916 . . . . 0.0 110.225 -179.935 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 6.3 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.285 0.564 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 23.0 t -104.4 56.07 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.324 -0.86 . . . . 0.0 109.733 179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.509 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 2.0 p-80 -47.25 128.64 12.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.396 -0.815 . . . . 0.0 110.602 -179.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 34.8 m -81.93 -34.2 29.98 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.228 -0.92 . . . . 0.0 109.559 179.209 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -146.54 -60.61 0.3 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.447 -0.783 . . . . 0.0 110.092 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' MET . . . . . 0.53 ' HG3' ' N ' ' A' ' 7' ' ' GLU . 17.1 ptm -176.51 -36.03 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.393 -0.817 . . . . 0.0 109.809 179.813 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.53 ' N ' ' HG3' ' A' ' 6' ' ' MET . 6.4 tt0 -107.05 -49.91 3.19 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.384 -0.822 . . . . 0.0 109.891 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 1.6 t -86.39 104.68 14.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.275 -0.891 . . . . 0.0 109.624 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.476 HD13 ' C ' ' A' ' 9' ' ' ILE . 0.0 OUTLIER -123.89 158.94 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.2 -0.938 . . . . 0.0 110.216 -179.775 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -120.21 156.0 55.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 O-C-N 121.155 -0.966 . . . . 0.0 109.91 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.532 ' HG2' ' CD1' ' A' ' 14' ' ' TYR . 44.1 Cg_endo -82.09 32.98 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.592 0 O-C-N 123.764 1.402 . . . . 0.0 111.267 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 11' ' ' PRO . 19.1 t0 66.59 -56.31 0.4 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.101 -0.999 . . . . 0.0 111.183 179.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 11' ' ' PRO . . . -44.05 -23.71 0.45 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' TYR . . . . . 0.627 ' CD1' ' N ' ' A' ' 14' ' ' TYR . 13.7 m-85 -112.92 173.08 6.56 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.031 -1.276 . . . . 0.0 110.913 -179.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.486 ' O ' ' HA ' ' A' ' 26' ' ' CYS . 4.4 p -106.46 135.19 48.4 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 179.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 25' ' ' GLY . 4.0 t -88.7 104.47 16.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.926 -1.109 . . . . 0.0 111.251 -178.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 32.1 p -106.76 139.33 41.36 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.447 -0.783 . . . . 0.0 109.207 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.578 ' HG3' ' CE2' ' A' ' 24' ' ' TRP . 7.1 ttt180 -77.81 137.56 38.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.001 -1.062 . . . . 0.0 110.809 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . 0.898 ' HB2' ' HB3' ' A' ' 23' ' ' ALA . 0.2 OUTLIER -73.96 177.86 1.9 Allowed Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.51 -0.744 . . . . 0.0 109.968 179.766 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.542 ' HD2' ' CG ' ' A' ' 19' ' ' LEU . 45.7 Cg_endo -72.73 -11.12 25.75 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.931 1.49 . . . . 0.0 110.408 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.9 t -108.83 28.47 8.41 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.181 -0.949 . . . . 0.0 110.133 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.08 12.07 79.25 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.898 ' HB3' ' HB2' ' A' ' 19' ' ' LEU . . . -85.62 -172.95 4.38 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.29 -1.123 . . . . 0.0 110.258 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.578 ' CE2' ' HG3' ' A' ' 18' ' ' ARG . 27.7 m95 -137.28 147.19 45.52 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.342 -0.849 . . . . 0.0 109.875 179.565 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.494 ' O ' ' HA ' ' A' ' 16' ' ' CYS . . . -143.79 151.99 23.81 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 -179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.486 ' HA ' ' O ' ' A' ' 15' ' ' THR . 7.5 m -108.58 107.02 17.35 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.298 -1.119 . . . . 0.0 110.08 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -98.78 132.88 23.01 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.185 -0.947 . . . . 0.0 109.945 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.52 ' HB3' ' CE2' ' A' ' 14' ' ' TYR . 44.4 Cg_endo -72.48 149.72 50.53 Favored 'Trans proline' 0 C--N 1.303 -1.858 0 O-C-N 123.68 1.358 . . . . 0.0 110.783 -179.597 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 3.0 t80 -117.1 99.41 7.03 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.386 -0.821 . . . . 0.0 110.229 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.66 HG23 ' O ' ' A' ' 30' ' ' THR . 6.1 t -144.41 101.17 3.65 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.282 -0.886 . . . . 0.0 110.013 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 9.6 mm100 . . . . . 0 N--CA 1.493 1.676 0 O-C-N 121.276 -0.89 . . . . 0.0 110.189 -179.799 . . . . . . . . 0 0 . 1 stop_ save_